

1. Gustafsson, J. Å. and Ingelman Sundberg, M.: Sex specific 15 α hydroxylation of sulphoconjugated 5 α androstane 3 β ,17 β diol in liver microsomes from female rats. FEBS Lett., 1973, 31: 292 296.
2. Gustafsson, J. Å. and Ingelman Sundberg, M.: Regulation and properties of a sex specific hydroxylase system in female rat liver microsomes active on steroid sulfates. I. General characteristics. J. Biol. Chem., 1974, 249: 1940 1945.
3. Gustafsson, J. Å. and Ingelman Sundberg, M.: Age dependent induction and repression of rat liver microsomal hydroxylase systems by estradiol. Biochim. Biophys. Acta, 1974, 354: 172 181.
4. Gustafsson, J. Å., Ingelman Sundberg, M., Stenberg, Å. and Neumann, F.: Partial feminization of hepatic steroid metabolism in male rats following neonatal administration of cyproterone acetate. J. Endocrinol., 1975, 64: 267 275.
5. Gustafsson, J. Å., Gustafsson, S.A., Ingelman Sundberg, M., Pousette, Å., Stenberg, Å. and Wrangé, Ö.: Sexual differentiation of hepatic metabolism in the rat. J. Steroid Biochem., 1974, 5: 855 859.
6. Gustafsson, J. Å. and Ingelman Sundberg, M.: Regulation and substrate specificity of a steroid sulfate specific hydroxylase system in female rat liver microsomes. J. Biol. Chem., 1975, 250: 3451 3458.
7. Ingelman Sundberg, M., Rane, A. and Gustafsson, J. Å.: Properties of hydroxylase systems in the human fetal liver active on free and sulphoconjugated steroids. Biochemistry, 1975, 14: 429 437.
8. Gustafsson, J. Å., Ingelman Sundberg, M. and Stenberg, Å.: Neonatal androgen programming of hepatic steroid metabolism in rats. J. Steroid Biochem., 1985, 6: 643 650.
9. Gustafsson, J. Å. and Ingelman Sundberg, M.: Multiple forms of cytochrome P 450 in rat liver microsomes. Separation and some properties of different hydroxylase systems active on free and sulphoconjugated steroids. Eur. J. Biochem., 1976, 64: 35 43.
10. Hrycay, E., Gustafsson, J. Å., Ingelman Sundberg, M. and Ernster, L.: The involvement of cytochrome P 450 in hepatic microsomal steroid hydroxylation reactions supported by sodium periodate, sodium chlorite, and organic hydroperoxides. Eur. J. Biochem., 1976, 61: 43 52.
11. Einarsson, K., Gustafsson, J. Å., Ihre, T. and Ingelman Sundberg, M.: Specific metabolic pathways of steroid sulfates in human liver microsomes. J. Clin. Endocrinol. Metab., 1976, 43: 56 63.
12. Ingelman Sundberg, M.: Specific reductive metabolism of steroid sulphates in rat liver. Biochim. Biophys. Acta, 1976, 431: 592 602.
13. Hrycay, E., Gustafsson, J. Å., Ingelman Sundberg, M. and Ernster, L.: Sodium periodate, sodium chlorite, and organic hydroperoxides as hydroxylating agents in hepatic microsomal steroid hydroxylations catalyzed by cytochrome P 450. FEBS Lett., 1975, 56: 161 165.
14. Berg, A., Carlström, K., Gustafsson, J. Å. and Ingelman Sundberg, M.: Demonstration of a cytochrome P 450 dependent steroid 15 β hydroxylating

- system in *Bacillus megaterium*. *Biochem. Biophys. Res. Commun.*, 1975, 66: 1414 1423.
15. Ingelman Sundberg, M.: Phospholipids and detergents as effectors in cytochrome P 450 catalyzed reactions. *Biochim. Biophys. Acta*, 1977, 488: 225 234.
 16. Berg, A., Carlström, K., Ingelman Sundberg, M. and Gustafsson, J. Å.: Characterization of a cytochrome P 450 dependent hydroxylase system present in *Bacillus megaterium*. *J. Biol. Chem.*, 1976, 251: 2831 2838.
 17. Hrycay, E., Gustafsson, J. Å., Ingelman Sundberg, M. and Ernster, L.: Sodium periodate, sodium chlorite, organic hydroperoxides and H₂O₂ as hydroxylating agents in steroid hydroxylation reactions catalyzed by partially purified cytochrome P 450. *Biochem. Biophys. Res. Commun.*, 1975, 66: 209 216.
 18. Gustafsson, J. Å., Hökfelt, T., Ingelman Sundberg, M. and Stenberg ??: Feminization of hepatic steroid metabolism in male rats following electrothermic lesion of the hypothalamus. *Endocrinology*, 1976, 98: 922 926.
 19. Rydström, J., Gustafsson, J. Å., Ingelman Sundberg, M., Montelius, J. and Ernster, L.: The topology of the mitochondrial 11 β hydroxylase system in bovine adrenal cortex. *Biochem. Biophys. Res. Commun.*, 1975, 73: 555 561.
 20. Ingelman Sundberg, M. and Gustafsson, J. Å.: Resolution of multiple forms of phenobarbital induced liver microsomal cytochrome P 450 by electrofocusing on granulated gels. *FEBS Lett.*, 1977, 74: 103 106.
 21. Montelius, J., Gustafsson, J. Å., Ingelman Sundberg, M. and Rydström, J.: Binding and hydroxylation of sulphotoconjugated steroids in adrenal cortex mitochondria. *Biochim. Biophys. Acta*, 1977, 488: 502 511.
 22. Ingelman Sundberg, M. and Glaumann, H.: Reconstitution of the liver microsomal hydroxylase system into liposomes. *FEBS Lett.*, 1977, 78: 72 76.
 23. Ingelman Sundberg, M.: Hepatic metabolism of steroid sulphates with special reference to cytochrome P 450 catalyzed reactions. Thesis, 1975.
 24. Berg, A., Ingelman Sundberg, M. and Gustafsson, J. Å.: Purification and characterization of cytochrome P 450_{meg}. *J. Biol. Chem.*, 1979, 254: 5264 5271.
 25. Ingelman Sundberg, M., Montelius, J., Rydström, J. and Gustafsson, J. Å.: The active form of cytochrome P 450 11 β from adrenal cortex mitochondria. *J. Biol. Chem.*, 1978, 253: 5042 5047.
 26. Nielsen, O., Toftgård, R., Ingelman Sundberg, M. and Gustafsson, J. Å.: Qualitative alterations of cytochrome P 450 in mouse liver microsomes after administration of acrylamide and methylmethacrylate. *Acta Pharm. Tox.*, 1978, 43: 299 305.
 27. Rafter, J., Ingelman Sundberg, M. and Gustafsson, J. Å.: Protein amino acid analysis by an isotope radio gas chromatography mass spectrometry computer technique. *Biomed. Mass Spec.*, 1979, 6: 317 324.
 28. Halpert, J., Glaumann, H. and Ingelman Sundberg, M.: Isolation and incorporation of rabbit liver epoxide hydrolase into phospholipid vesicles. *J. Biol. Chem.*, 1979, 254: 7434 7441.
 29. Rydström, J., Ingelman Sundberg, M., Montelius, J. and Gustafsson, J. Å.: Molecular properties of cytochrome P 450 11 β from adrenal cortex mitochondria. *Acta Biol. Med. Germ.*, 1979, 38: 275 285.

30. Ingelman Sundberg, M., Johansson, I. and Hansson, A.: Catalytic properties of the liver microsomal hydroxylase system in reconstituted phospholipid vesicles. *Acta Biol. Med. Germ.*, 1979, 38: 379 388.
31. Ingelman Sundberg, M. and Gustafsson, J. Å.: Changes in steroid hormone metabolism in rat liver microsomes following administration of 2,3,7,8 tetrachlorodibenzo-p dioxine (TCDD). *Biochem. Pharmacol.*, 1979, 28: 497 499.
32. Rafter, J., Ingelman Sundberg, M. and Gustafsson, J. Å.: Gas chromatography mass spectrometry in analysis of protein amino acid composition. *Acta Biol. Med. Germ.*, 1979, 38: 321 331.
33. Berg, A., Ingelman Sundberg, M. and Gustafsson, J. Å.: Isolation and characterization of cytochrome P 450_{meq}. *Acta Biol. Med. Germ.*, 1979, 38: 333 344.
34. Toftgård, R., Nielsen, O., Ingelman Sundberg, M. and Gustafsson, J. Å.: Correlation between changes in enzymatic activities and induction of different forms of rat liver microsomal cytochrome 450 after phenobarbital 3 methylcholantrene and 16a cyanopregnenolone treatment. *Acta Pharm. Tox.*, 1979, 46: 353 361.
35. Ingelman Sundberg, M. and Glaumann, H.: Incorporation of purified components of the rabbit liver microsomal hydroxylase systems into phospholipid vesicles. *Biochim. Biophys. Acta*, 1980, 599: 417 435.
36. Ingelman Sundberg, M. and Johansson, I.: Catalytic properties of purified forms of rabbit liver microsomal cytochromes P 450 in reconstituted phospholipid vesicles. *Biochemistry*, 1980, 14: 4004 4011.
37. Ingelman Sundberg, M.: Bioactivation or inactivation of toxic ompounds? *Trends Pharmacol. Sci.*, 1980, 1: 176 179 (invited).
38. Brunström, A. and Ingelman Sundberg, M.: Benzo(a)pyrene metabolism by purified forms of rabbit liver microsomal cytochrome P 450, cytochrome b5 and epoxide hydrase in reconstituted phospholipid vesicles. *Biochem. Biophys. Res. Commun.*, 1980, 95: 431 439.
39. Ingelman Sundberg, M., Haaparanta, T. and Rydström, J.: Membrane charge as effector of cytochrome P 450 LM2 catalyzed reactions in reconstituted liposomes. *Biochemistry*, 1981, 20: 4004 4011.
40. Ingelman Sundberg, M. and Johansson, I.: Cytochrome b5 as electron donor to rabbit liver cytochrome P 450 in reconstituted phospholipid vesicles. *Biochem. Biophys. Res. Commun.*, 1980, 97: 582 589.
41. Ingelman Sundberg, M. and Johansson, I.: The mechanism of cytochrome P 450 dependent oxidation of ethanol in reconstituted membrane vesicles. *J. Biol. Chem.*, 1981, 256: 6321 6326.
42. Bäckström, D., Ingelman Sundberg, M. and Ehrenberg, A.: Oxidation reduction potential of soluble and membrane bound rabbit liver microsomal cytochrome P 450 LM2. *Acta Chem. Scand. Ser. B*, 1983, 37: 891 894.
43. Ekström, G., Glaumann, H., von Bahr, C. and Ingelman Sundberg, M.: Interindividual variation in benzo(a)pyrene metabolism and composition of isoenzymes of cytochrome P 450 as revealed by SDS gelelectrophoresis of human liver microsomal fractions. *Acta Pharm. Tox.*, 1982, 50: 251 260.

44. Ingelman Sundberg, M. and Johansson, I.: Electron flow and complex formation during cytochrome P 450 catalyzed hydroxylation reactions in reconstituted membrane vesicles. *Acta Chem. Scand. Ser. B*, 1984, 38: 845 851.
45. Ingelman Sundberg, M. and Ekström, G.: Aniline is hydroxylated by the cytochrome P 450 dependent hydroxyl radical mediated oxygenation mechanism. *Biochem. Biophys. Res. Commun.*, 1982, 106: 625 631.
46. Ingelman Sundberg, M. and Hagbjörk, A. L.: On the significance of the cytochrome P 450 dependent hydroxyl radical mediated oxygenation mechanism. *Xenobiotica*, 1982, 12: 673 686 (invited).
47. Ingelman Sundberg, M., Blanck, J., Smettan, G. and Ruckpaul, K.: Reduction of cytochrome P 450 LM2 by NADPH in reconstituted phospholipid vesicles is dependent on membrane charge. *Eur. J. Biochem.*, 1983, 134: 157 162.
48. Johansson, I. and Ingelman Sundberg, M.: Hydroxyl radical mediated, cytochrome P 450 dependent metabolic activation of benzene in microsomes and reconstituted systems from rabbit liver. *J. Biol. Chem.*, 1983, 258: 7311 7316.
49. Luthman, H. and Ingelman Sundberg, M.: Cytochrome P 450 dependent Fragmentation of DNA in Reconstituted Membranes. *Acta Pharm. Tox.*, 1985, 56: 69 74.
50. Ingelman Sundberg, M. and Johansson, I.: Mechanisms of hydroxyl radical formation of ethanol oxidation by ethanol inducible and other forms of rabbit liver microsomal cytochromes P 450. *J. Biol. Chem.*, 1984, 259: 6447 6458.
51. Ingelman Sundberg, M. and Jörnvall, H.: Induction of the ethanol inducible form of rabbit liver microsomal cytochrome P 450 by inhibitors of alcohol dehydrogenase. *Biochem. Biophys. Res. Commun.*, 1984, 124: 375 382.
52. Ekström, G. and Ingelman Sundberg, M.: Cytochrome P 450 dependent lipid peroxidation in reconstituted membrane vesicles. *Biochem. Pharmacol.*, 1984, 33: 2521 2423.
53. Blanck, J., Smettan, G., Ristau, O., Ingelman Sundberg, M. and Ruckpaul, K.: Mechanism of rate control of the NADPH dependent reduction of cytochrome P 450 by lipids in reconstituted phospholipid vesicles. *Eur. J. Biochem.*, 1984, 144: 509 513.
54. Skoglund, G., Hansson, A. and Ingelman Sundberg, M.: Characterization of calcium and phospholipid dependent protein kinase in isolated rat adipocytes. *Acta Chem. Scand. Ser B.*, 1985, 39: 219 226.
55. Skoglund, G., Hansson, A. and Ingelman Sundberg, M.: Rapid effects of phorbol esters on isolated rat adipocytes. Relationship to the action of protein kinase C. *Eur. J. Biochem.*, 1985, 148: 407 412.
56. Johansson, I. and Ingelman Sundberg, M.: Carbon tetrachloride induced lipid peroxidation dependent on an ethanol inducible form of rabbit liver microsomal cytochrome P 450. *FEBS Lett.*, 1985, 183: 265 269.
57. Ekström, G., Cronholm, T. and Ingelman Sundberg, M.: Hydroxyl radical production and ethanol oxidation by liver microsomes isolated from ethanol treated rats. *Biochem. J.*, 1986, 233: 755 761.
58. Forsbeck, K., Nilsson, K., Hansson, A., Skoglund, G. and Ingelman Sundberg, M.: Phorbol ester induced alteration of differentiation and proliferation in human

- hematopoietic tumor cell lines: Relationship to the presence and subcellular distribution of protein kinase C. *Cancer Res.*, 1985, 45: 6194-6199.
59. Ekström, G. and Ingelman Sundberg, M.: Mechanism of lipid peroxidation dependent upon cytochrome P 450 LM2. *Eur. J. Biochem.*, 1986, 158: 195-201.
 60. Hansson, A. and Ingelman Sundberg, M.: Insulin stimulated protein synthesis in adipocytes. Enhanced rate of initiation associated with increased phosphorylation of ribosomal protein S6. *Eur. J. Biochem.*, 1985, 151: 97-100.
 61. Johansson, I., Eliasson, E., Norsten, C. and Ingelman Sundberg, M.: Hydroxylation of acetone by ethanol and acetone inducible cytochrome P 450 in liver microsomes and reconstituted membranes. *FEBS Lett.*, 1986, 196: 59-64.
 62. Hansson, A., Serhan, C.N., Haeggström, J., Ingelman Sundberg, M. and Samuelsson, B.: Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. *Biochem. Biophys. Res. Commun.*, 1986, 134: 1215-1222.
 63. Hansson, A. and Ingelman Sundberg, M.: Modulation of the substrate specificity of purified human protein kinase C by its activators. *Acta Chem. Scand. Ser. B*, 1987, B41: 174-179.
 64. Ingelman Sundberg, M. and Paul, K.G.: Heme release from rabbit liver microsomal cytochrome P 450 LM2. *Acta Chem. Scand. Ser. B*, 1986, 40: 233-234.
 65. Ekström, G., Norsten, C., Cronholm, M. and Ingelman Sundberg, M.: Cytochrome P 450 dependent ethanol oxidation: Kinetic isotope effects and absence of stereoselectivity. *Biochemistry*, 1987, 26: 7348-7354.
 66. Terelius, Y. and Ingelman Sundberg, M.: Metabolism of n-pentane by ethanol inducible cytochrome P 450 in liver microsomes and reconstituted membranes. *Eur. J. Biochem.*, 1986, 161: 303-308.
 67. Forsbeck, K., Nilsson, K., Nygren, P., Larsson, R., Gylfe, E., Skoglund, G. and Ingelman Sundberg, M.: Phorbol ester induced stable changes in the regulation of DNA synthesis and intracellular pH are accompanied by altered expression of protein kinase C in the monoblastoid cell line U 937. *Int J Cancer*, 1988, 42: 284-288.
 68. Johansson, I., Ekström, G., Scholte, B., Puzycki, D., Jörnvall, and Ingelman Sundberg, M.: Ethanol, fasting and acetone inducible cytochromes P 450 in rat liver. Regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. *Biochemistry*, 1988, 27: 1925-1934.
 69. Johansson, I. and Ingelman Sundberg, M.: Benzene metabolism by ethanol and acetone and benzene-inducible cytochrome P 450 (IIE1) in rat and liver microsomes. *Cancer Res.*, 1988, 48: 5387-5390.
 70. Eliasson, E., Johansson, I. and Ingelman Sundberg, M.: Ligand dependent maintenance of ethanol inducible cytochrome P 450 in primary rat hepatocyte cell cultures. *Biochem. Biophys. Res. Commun.*, 1988, 150: 436-443.
 71. Terelius, Y. and Ingelman Sundberg, M.: Cytochrome P 450 dependent oxidase activity and hydroxyl radical production in micellar and membranous types of reconstituted systems. *Biochem. Pharmacol.*, 1988, 37: 1383-1389.

72. Skoglund, G., Patarroyo, M., Forsbeck, K., Nilsson, K. and Ingelman Sundberg, M.: Evidence for separate control by phorbol esters of CD18 dependent adhesion and translocation of protein kinase C in U 937 cells. *Cancer Res.*, 1988, 48: 3168 3172.
73. Tindberg, N. and Ingelman Sundberg, M.: Cytochrome P 450 and oxygen toxicity. Oxygen-dependent induction of ethanol inducible cytochrome P 450 (IIE1) in rat liver and lung. *Biochemistry*, 1989, 28: 4499 4504.
74. Hansson, A., Skoglund, G., Lassing, I., Lindberg, U. and Ingelman Sundberg, M.: Protein kinase C dependent phosphorylation of profilin is specifically stimulated by phosphatidylinositol biophosphate (PIP2). *Biochem. Biophys. Res. Commun.*, 1988, 150: 526 531.
75. Ekström, G., von Bahr, C. and Ingelman Sundberg, M.: Human liver microsomal cytochrome P 450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity. *Biochem. Pharmacol.*, 1989, 38: 689 693.
76. Norsten, C., Cronholm, T., Ekström, G., Handler, J., Thurman, R.G. and Ingelman Sundberg, M.: Dehydrogenase dependent ethanol metabolism in deermice (*Peromyscus maniculatus*) lacking cytosolic alcohol dehydrogenase: Reversibility and isotope effects in vivo and in subcellular systems. *J. Biol. Chem.*, 1989, 264: 5593 5597.
77. Ekström, G. and Ingelman Sundberg, M.: Rat liver microsomal NADPH supported oxidase activity and lipid peroxidation dependent on ethanol inducible cytochrome P 450. *Biochem. Pharmacol.*, 1989, 38: 1313 1319.
78. Ingelman Sundberg, M., Johansson, I., Penttilä, K. E., Glaumann, H. and Lindros, K.O.: Centrilobular expression of ethanol inducible cytochrome P 450 (IIE1) in rat liver. *Biochem. Biophys. Res. Commun.*, 1988, 157: 55 60.
79. Skoglund, G., Cotgreave, I., Rincon, J., Patarroyo, M. and Ingelman Sundberg, M.: H₂O₂ activates CD11b/CD18 dependent cell adhesion. *Biochem. Biophys. Res. Commun.*, 1988, 157: 443 449.
80. Ronis, M. J. J. and Ingelman Sundberg, M.: Acetone dependent regulation of cytochrome P 450j (IIE1) and P 450b (IIB1) in rat liver. *Xenobiotica*, 1989, 19: 1161 1168 (invited).
81. Hansson, T., Tindberg, N., Ingelman Sundberg, M. and Köhler, C.: Regional distribution of ethanol inducible cytochrome P 450 IIE1 in the rat central nervous system. *Neuroscience*, 1990, 34: 451 463.
82. Yue, Q. Y., Bertilsson, L., Puustinen Dahl, M. L. Säwe, J. Sjöqvist, F., Johansson, I. and Ingelman Sundberg, M.: Dissociation between debrisoquine hydroxylation phenotype and genotype among Chinese. *Lancet*, ii: Oct 7, 1989, p 870.
83. Wallin, H., Mikalsen, A., Guengerich, F. P., Ingelman Sundberg, M., Solberg, K., E., Rossland, O. J., and Alexander, J.: Differential rates of metabolic activation and detoxication of the food mutagen 2 amino 1 methyl 6 -phenylimidazo[4,5 b]pyridine by different cytochrome P450 enzymes, *Carcinogenesis*, 1990, 11: 489-492.
84. Yue, Q. Y., Bertilsson, L., Puustinen Dahl, M. L., Säwe, J., Sjöqvist, F., Johansson, I. and Ingelman Sundberg, M.: Debrisoquine phenotype and genotype among Chinese. *Lancet* ii: 1989, 1534.

85. Johansson, I., Eliasson, E. and Ingelman Sundberg, M.: Hormone controlled phosphorylation and degradation of CYP2B1 and CYP2E1 in isolated rat hepatocytes. *Biochem. Biophys. Res. Commun.*, 1991, 174: 37-42.
86. Johansson, I., Lindros, K. O., Eriksson, H. and Ingelman Sundberg, M.: Transcriptional control of CYP2E1 in the perivenous liver region and during starvation, *Biochem. Biophys. Res. Commun.*, 1990, 173: 331-338.
87. Persson, J. O., Terelius, Y. and Ingelman Sundberg, M: Cytochrome P 450 dependent formation of reactive oxygen radicals: isozyme specific inhibition of P 450 mediated reduction of oxygen and carbon tetrachloride. *Xenobiotica* 1990, 20: 887 900. (invited)
88. Eliasson, E., Johansson, I. and Ingelman Sundberg, M.: Substrate, hormone and cAMP regulated cytochrome P450 degradation, *Proc. Natl. Acad. Sci (USA)*, 1990, 87: 3225-3229.
89. Ingelman Sundberg, M., Kaur, H., Terelius, Y., Persson, J. O. and Halliwell, B.: Hydroxylation of salicylate by microsomal fractions and cytochrome P 450. Lack of production of 2,3 dihydroxybenzoate unless hydroxyl radical formation is permitted. *Biochem. J.* 1991, 276: 753-757.
90. Bühler, R., Lindros, K. O., von Boguslawsky, K., Kärkkäinen, P., Mäkinen, J. and Ingelman Sundberg, M.: Perivenous expression of ethanol inducible cytochrome P450IIE1 in livers from alcoholics and chronically ethanol fed rats. *Alcohol & Alcoholism*, 1991, suppl 1: 311-315.
91. Albano, E., Tomasi, A., Persson, J. O., Terelius, Y., Gorla Gatti, L., Ingelman Sundberg, M. and Dianzani, M. U.: Role of ethanol inducible cytochrome P 450 (P 450IIE1) in catalysing the free radical activation of aliphatic alcohols. *Biochem. Pharmacol.*, 1991, 41: 1895-1902.
92. Ronis, M. J. J., Lumpkin, C. K., Ingelman Sundberg, M. and Badger, T. M.: Effects of short term ethanol and nutrition on the hepatic microsomal monooxygenase system in a model utilizing total enteral nutrition in the rat. *Alcoholism: Clin. Exp. Res.*, 1991, 15: 693-699.
93. Ronis, M. J. J., Johansson, I., Hultenby, K., Lagercrantz, J., Glaumann, H. and Ingelman Sundberg, M.: Acetone regulated synthesis and degradation of cytochromes P450IIE1 and P450IIB1 in rat liver. *Eur J Biochem*, 1991, 198: 383-389.
94. Halliwell, B., Kaur, H. and Ingelman Sundberg, M.: Hydroxylation of salicylate as an assay for hydroxyl radicals: A cautionary note. *Free Rad Biol Med*, 1991, 10: 439-441.
95. Bühler, R., Lindros, K. O., Nordling, Å., Johansson, I. and Ingelman Sundberg, M.: Zonation of cytochrome P450 isozyme expression and induction in rat liver. *Eur J Biochem*, 1992, 204: 407-412.
96. Ronis, M. J. J., Thomas, P. E., Ingelman Sundberg, M., Badger, T. M. and Lumpkin, C. K.: The microsomal monooxygenase system of regenerating liver: An examination of the role of estradiol in the demasculinization of drug metabolism produced by 2/3 partial hepatectomy. *Biochem. Pharmacol*, 1992, 43: 567-573.
97. Takahashi, H., Johansson, I., French, S. W. and Ingelman-Sundberg, M.: Effects of dietary fat composition on activities of the microsomal ethanol oxidizing system

- and ethanol inducible cytochrome P450 in the liver of rats chronically fed ethanol. *Pharmacol. Toxicol.*, 1992, 70: 347-352.
98. Cronholm, T., Norsten Höög, C., Ekström, G., Handler, J., Thurman, R. G. and Ingelman Sundberg, M.: Oxidoreduction of butanol in deer mice (*Peromyscus maniculatus*) lacking hepatic cytosolic alcohol dehydrogenase. *Eur J Biochem*, 1992, 204: 353-358.
 99. Johansson, I., Yue, Q.Y., Dahl, M.-L., Heim, M., Bertilsson, L., Meyer, U.A., Sjöqvist, F. and Ingelman-Sundberg, M.: Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. *Eur J Clin Pharmacol* 1991, 40: 553-556.
 100. Dahl, M.-L., Johansson, I., Porsmyr-Palmertz, M., Ingelman-Sundberg, M. and Sjöqvist, F.: Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. *Clin Pharmacol Ther*, 1992, 52: 12-17.
 101. Terelius, Y., Norsten-Höög, C., Cronholm, T. and Ingelman-Sundberg, M.: Acetaldehyde as substrate for ethanol-inducible cytochrome P450 (CYP2E1). *Biochem Biophys Res Commun*, 1991, 179: 689-694.
 102. Mikalsen, A., Alexander, J., Wallin, H., Ingelman-Sundberg, M. and Andersen, R.A.: Reductive metabolism and protein binding of chromium (VI) by P450 protein enzymes. *Carcinogenesis* 1991, 12: 825-831.
 103. Mikalsen, A., Alexander, J., Andersen, R.A. and Ingelman-Sundberg, M.: Effect of in vivo chromate, acetone and combined treatment on rat liver in vitro microsomal chromium (VI) reductive activity and on cytochrome P450 expression. *Pharmacol Toxicol*, 1991, 68: 456-463.
 104. Shan, X., Aw, T.Y., Smith, E.R., Ingelman-Sundberg, M., Mannervik, B., Yanagi, T. and Jones, D.P.: Effect of chronic hypoxia on detoxication enzymes in rat liver. *Biochem Pharmacol* 1992, 43: 2421-2426.
 105. Ingelman-Sundberg, M., Eliasson, E. and Johansson, I.: Läkemedelsmetabolismen är dynamisk. Lika anpassningsbar som immunsystemet. *Läkartidningen*. 1991, 88: 28-29.
 106. Ingelman-Sundberg, M., and Ekström, G.: Multiple roles of cytochrome P450 in lipid peroxidation. in "Biological Free Radical Reactions and Antioxidants" (Cadenas, E, Ed), Cleup University Publisher, 1992, 43-47.
 107. Albano, E., Ingelman-Sundberg, M., Tomasi, A. and Poli, G.: Free radical mediated reactions and ethanol toxicity: Some considerations on the methodological approaches. *Alcoholism: A Molecular Perspective*. (Palmer, TN, Ed) Plenum Press New York, 1991, 45-56.
 108. French, S.W., Wong, K., Jui, L., Albano, E., Hagbjörk, A.-L. and Ingelman-Sundberg, M.: Effect of ethanol on cytochrome P450 (CYP2E1), lipid peroxidation and serum protein adduct formation in relation to liver pathology pathogenesis. *Exp Mol Pathol*, 1993, 58: 61-75.
 109. Ingelman-Sundberg, M., Johansson, I., Dahl, M.-L., Bertilsson, L., Yue, Q.-Y. and Sjöqvist, F.: Genotypning för läkemedelsmetabolisk förmåga kan ge värdefull klinisk information. *Läkartidningen*. 1992, 89: 1675- 1678.

110. Kobusch, A.-B., Schrenk, D., Gans, G., Münzel, P., Werringloer, J., Ingelman-Sundberg, M. and Bock, K.B.: Immunochemical localization and functional characterization of cytochrome P-450IIE1 in rat hepatocyte foci and nodules. *Carcinogenesis*, 1992, 12: 2353-2356.
111. Mendez, C.F., Hansson, A., Skoglund, G., Ingelman-Sundberg, M. Aperia, A.: Protein kinase C activity in rat renal proximal tubule cells. *Acta Physiol Scand*. 1992, 146: 135-140.
112. Schrenk, D., Ingelman-Sundberg, M. and Bock, K.W.: Influence of P4502E1 induction on benzene metabolism in rat hepatocytes and on biliary metabolite excretion, *Drug Met Disp*, 1992, 20: 137-141.
113. Ekström, G., Cronholm, T., Norsten-Höög, C. and Ingelman-Sundberg, M.: Dehydrogenase-dependent metabolism of alcohols in gastric mucosa of deer mice lacking hepatic alcohol dehydrogenase., *Biochem Pharmacol*, 1993, 45: 1989-1993.
114. Eliasson, E., Mkrtchian S, and Ingelman-Sundberg, M.: Hormone- and substrate regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes *J. Biol. Chem*. 1992, 267: 15765-15769.
115. Eliasson, E. Mkrtchian, S, Halpert, J. and Ingelman-Sundberg, M.: Substrate-regulated cAMP-dependent phosphorylation, denaturation and degradation of glucocorticoid-inducible rat liver cytochrome P450 3A1, *J. Biol. Chem*, 1994, 269:18378-18383.
116. Persson, I., Johansson, I., Bergling, H., Dahl, M.-L., Högberg, J., Rannug, A. and Ingelman-Sundberg, M.: Genetic polymorphism of CYP2E1 in a Swedish population. Relationship to the occurrence of lung cancer. *FEBS lett*. 1993, 319: 207-211.
117. Johansson, I. Oscarson, M., Yue, Q Y, Bertilsson, L., Sjöqvist, F., and Ingelman-Sundberg, M.: Genetic analysis of the Chinese CYP2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. *Mol Pharmacol* 1994, 46: 452-459,.
118. Hansson, T., von Bahr, C., Marklund, M., Svensson, J. O., Ingelman Sundberg, M. and Lundström, J.: Different regioselectivity in the hydroxylation of the antidepressant desmethylinipramine between rat brain and liver. *Pharmacol & Toxicol*, 1993, 71: 416-420.
119. Hu, Y, Mishin, V., Johansson, I., von Bahr, C., Cross, C., Ronis, M.J.J., Badger, T.M. and Ingelman-Sundberg, M.: Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver. *J Pharm Exp Ther*, 1994, 269:1286-1291.
120. Johansson, I., Bertilsson, L., Dahl, M-L, Sjöqvist, F and Ingelman-Sundberg, M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. *Proc Natl Acad Sci (USA)*, 1993, 90: 11825-11829. Commentary by Urs Meyer in *Proc Natl Acad Sci (USA)* 1994, 91: 1983-1984.
121. Ingelman-Sundberg, M., Johansson, I., Persson, I., Lundqvist, E. and Dahl. M.-L.: Genetic polymorphisms of cytochromes P450: Interethnic differences and

- relationship to incidence of lung cancer *Pharmacogenetics* 1992, 2: 264-271.
(invited).
122. Bertilsson, L. Meese, C.O., Yue, Q.Y., Dahl, M.-L., Eichelbaum, M., Ingelman-Sundberg, M., Johansson, I., Säwe, J. and Sjöqvist, F.: Quinidine inhibition of debrisoquine on the S(+)-4- and 7-hydroxylations in Chinese of different CYP2D genotypes. *Pharmacogenetics*, 1993, 3: 94-100.
 123. Dahl, M.-L., Iselius, L., Alm, A., Svensson, J.-O., Johansson, I., Ingelman-Sundberg, M. and Sjöqvist, F.: Polymorphic 2-hydroxylation of desipramine - a population and family study. *Eur J Clin Pharmacol*, 1993, 44: 445-450.
 124. Houde, M., Bracke, M., Skoglund, G., Ingelman-Sundberg, M., Masure, S., van Damme, J. and Opdenakker, G: Differential regulation of gelatinase B and tissue-type plasminogen activator expression in human Bowes melanoma cells. *Int J Cancer*, 1993, 53: 395-400.
 125. Badger, T.M., Ronis, M.J.J., Lumpkin, C.K., Shahare, M., Irby, D., Huang, J., Mercado, C., Valentine, C.R., Thomas, P., Ingelman-Sundberg, M. and Crough, J.: Effects of chronic ethanol on growth hormone secretion and hepatic cytochrome P450 isozymes of the rat, *J Pharm Exp Ther*, 1993, 264: 438-447.
 126. Ronis, M.J.J., Crough, J., Mercado, C., Irby, D., Valentine, C., Lumpkin, C.K., Ingelman-Sundberg, M. and Badger, T.M.: Cytochrome P450 CYP2E1 induction during alcohol exposure occurs by a two step mechanism associated with blood alcohol concentrations in rats, *J Pharm Exp Ther*, 1993, 264: 944-950.
 127. Bertilsson, L., Dahl, M.-L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson I., Lundqvist, E. and Ingelman-Sundberg, M. : Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. *Lancet* 1993, 341: 63.
 128. Longo, V. and Ingelman-Sundberg, M.: Acetone-dependent regulation of cytochromes P450 2E1 and P4502B1 in rat nasal mucosa. *Biochem Pharmacol*, 1993, 46: 1945-1951.
 129. Morimoto, M., Hagbjörk, A.-L., Nanji, A.A., Ingelman-Sundberg, M., Lindros, K.O., Albano, E., and French, S.W.: Role of cytochrome P450 2E1 in alcoholic liver disease pathogenesis. *Alcohol*, 1993, 10: 459-464.
 130. Ingelman-Sundberg, M., Johansson, I., Hu, Y., Terelius, Y., Eliasson, E., Clot, P., and Albano, E.: Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation and possible role in the etiology of alcohol-induced liver disease. *Alcohol*, 1993, 10: 447-452. (invited)
 131. Dahl, M.-L., Bertilsson, L., Ingelman-Sundberg, M., Johansson, I., Lundqvist, E and Sjöqvist, F.: Molecular basis of drug oxidation polymorphism. *Nord Psykiatrisk Tidsskrift*, suppl 30 1993, 27-31.
 132. Albano, E., Comoglio, A., Clot, P., Iannone, A., Tomasi, A. and Ingelman-Sundberg, M.: Activation of alkylhydrazines to free radical intermediates by ethanol-inducible cytochrome P-4502E1 (CYP2E1). *Biochim Biophys Acta*, 1995, 1243: 414-420.
 133. Badger, T.M., Ronis, M.J.J., Ingelman-Sundberg, M. and Hakkak, R.: Pulsatile blood alcohol and CYP2E1 induction during chronic alcohol infusions in rats. *Alcohol*, 1993, 10: 453-458.
 134. Muntane, J., Longo, V., Mitjavila, T., Gervasi, P.G., and Ingelman-Sundberg, M.: Effect of carrageenan-induced granuloma on the apoprotein content and activity

- of cytochrome P450 isozymes in liver and nasal mucosa in rats. *Inflammation*, 1995, 19: 143-156,.
135. Albano, E., Tomasi, A. and Ingelman-Sundberg, M.: ESR Spin trapping of alcohol-derived radicals in microsomes and reconstituted systems by electron spin resonance, *Meth Enzymol* 1994, 233: 117-127. (invited)
 136. Morimoto, M., Zern, M.A., Hagbjörk, A.L., Ingelman-Sundberg, M., and French, S.W. Fish oil, alcohol, and liver pathology: Role of cytochrome P450 2E1. *Proc Soc Exp Biol Med* 1994, 207: 197-205.
 137. Alexandrie, A.K., Ingelman-Sundberg, M., Seidegård, J., Tornling, G., and Rannug, A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types. *Carcinogenesis* 1994, 15:1785-1790.
 138. Ronis, M.J.J., Ingelman-Sundberg, M., and Badger, T.M. Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail (*Colinus virginianus*) by ergosterol biosynthesis inhibiting fungicides (EBIFs). *Biochem Pharmacol*, 1994, 48: 1953-1965.
 139. Zhukov, A, Werlinder, V, and Ingelman-Sundberg, M.: Purification and characterization of two membrane bound serine proteinases from rat liver microsomes active in degradation of cytochrome P450., *Biochem Biophys Res Commun*, 1993, 197: 221-228.
 140. Masimirembwa, C.M., Johansson, I., Hasler, J.A. and Ingelman-Sundberg, M.: Genetic polymorphism of cytochrome P450 2D6 in Zimbabwean population. *Pharmacogenetics*. 1993, 3: 275-280.
 141. Rannug,, A., Alexandrie, A-K., Persson, I and Ingelman-Sundberg, M.: Genetic polymorphism of cytochrome P450 1A1, 2D6 and 2E1. Regulation and toxicological significance. *J Occ Env. Med.* 1995, 37: 25-36,.
 142. Ronis, M.J.J., Hakkak, Ingelman-Sundberg, M and Badger, T.M.: Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. *Biochem Pharmacol* 1994, 48: 1823-1833,.
 143. Morimoto, M., Hagbjörk, A.-L., Yvonne- Y-J., Fu, P.C. Albano, E. Ingelman-Sundberg, M. and French, S.W.: Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors, *Hepatology*, 1995, 21:1610-1617.
 144. Masimirembwa, C., Bertilsson, L., Johansson, J., Hasler J.A. and Ingelman-Sundberg, M: Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe, *Clin Pharmacol Ther*, 1995, 57: 656-661.
 145. Hu, Y., Ingelman-Sundberg, M. and Lindros, K.O.: Induction mechanisms of cytochrome P450 2E1 in liver: Interplay between ethanol treatment and starvation, *Biochem Pharmacol*, 1995, 50: 155-161.
 146. Ronis, M.J.J., Huang, J., Longo, V., Tindberg, N. Ingelman-Sundberg, M. and Badger, T.M.: Expression and distribution of cytochrome P450 enzymes in male rat kidney: Effects of ethanol, acetone and dietary conditions, *Biochem Pharmacol.*, 1998, 55: 123-129.

147. Dahl, M.L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M and Sjöqvist, F.: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. *J Pharm Exp Ther*, 1995, 274: 516-520.
148. Schmalix, W.A., Barrenscheen, M., Landsiedel, R., Janzowski, C., Eisenbrand, G., Gonzalez, F.J., Eliasson, E., Ingelman-Sundberg, M., Perchermeier, M., Greim, H. and Doehmer, J.: Stable expression of human cytochrome P450 2E1 in V79 Chinese Hamster Cells and metabolic activation of p-nitrophenol, chlorzoxazone and N-nitrosodimethylamine. *Eur J Pharmacol*, 1995, 293: 123-131.
149. Morimoto, M., Reitz, R.C., Morin, R.J., Nguyen, K., Ingelman-Sundberg, M. and French, S.: CYP2E1 inhibitors partially ameliorate the changes in hepatic fatty acid composition induced in rats by chronic administration of ethanol and a high fat diet. *J Nutrition*, 1995, 125: 2953-2964.
150. Birgander, R., Sjölander, A., Rannug, A., Alexandrie, A.-K., Ingelman-Sundberg, M., Seidegård, J., Tornling, G., Beckman, G. and Beckman, L.: p53 polymorphisms and haplotypes in lung cancer. *Carcinogenesis*, 1995, 16: 2233-2236.
151. Hakkak, R., Korourian, S., Ronis, M.J.J., Ingelman-Sundberg, M., McGehee, R.E. and Badger, T.M.: Effects of diet and ethanol on expression and localization of cytochromes 2E1 and 2C7 in the colon of male rats. *Biochem Pharmacol*, 1996, 51: 61-69.
152. Hu, Y., Oscarson, M., Johansson, I., Yue, Q-Y, Dahl, M.L., Tabone, M., Arinco, S., Albano, E. and Ingelman-Sundberg, M.: Genetic polymorphism of the human CYP2E1 - Characterization of two variant alleles. *Mol Pharmacol*, 1996, 51: 370-376.
153. Lundqvist, E., Johansson, I., Dahl, M.-L. and Ingelman-Sundberg, M.: Genetic mechanism for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. *Gene*, 226:327-338, 1999.
154. McGehee, R.E., Ronis, M.J.J., Cowherd, R.M., Ingelman-Sundberg, M., and Badger, T.M. Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. *Biochem Pharmacol* 1994, 48:1823-1833.
155. Ronis, M.J.J., Lindros, K.O. and Ingelman-Sundberg, M.: The cytochrome P4502E subfamily in Cytochromes P450, Pharmacological and Toxicological Aspects (Ioannides, I., Ed.) CRC Press, 1996, pp 211-239. (invited)
156. Ingelman-Sundberg, M., Ronis, M.J.J., Lindros, K.O., Eliasson, E. and Zhukov, A.: Ethanol-inducible cytochrome P4502E1: Regulation, enzymology and molecular biology, in *Alcohol and Alcoholism*, 1995, suppl 2, pp. 133-141.
157. Lindros, K.O., Badger, T.M., Ronis, M.J.J., Ingelman-Sundberg, M. and Koivusalo, M.: Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor. *J Pharm Exp Ther*, 1995, 275: 79-83.
158. Gut, I., Nedelcheva, V., Soucek, P., Stopka, P., Gelboin, H.V. and Ingelman-Sundberg, M.: The role of CYP2E1 and 2B1 in metabolic activation of benzene derivatives. *Arch Toxicol*, 1996, 71: 45-56.
159. Badger, T.M., Ronis, M.J.J., Ingelman-Sundberg, M. and Hakkak, R: Inhibition of CYP2E1 activity does not abolish pulsatile urine alcohol concentrations during alcohol infusions. *Eur J Biochem*, 1995, 230: 914-919.

160. Albano, E., Clot, P., Morimoto, M., Tomasi, A., Ingelman-Sundberg, M. and French, S.: Role of cytochrome P4502E1-dependent formation of hydroxylethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. *Hepatology*, 1995, 23: 155-163.
161. Tindberg, N., Baldwin, H.A., Cross, and Ingelman-Sundberg, M.: Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. *Mol Pharmacol*, 1996, 50: 1065-1072.
162. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F and Ingelman-Sundberg, M.: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. *J Pharm Exp Ther*, 1996, 278: 441-446.
163. Backlund, M., Mkrtchian, S., Johansson, I. and Ingelman-Sundberg, M.: Signal transduction mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. *J Biol Chem* 1997, 272: 31755-31763.
164. Lindros, K.O., Oinonen, T., Johansson, I. and Ingelman-Sundberg, M.: Selective centrilobular expression of the aryl hydrocarbon receptor in rat liver. *J. Pharm Exp Ther*, 1997, 280: 506-511.
165. Stål, P., Johansson, I., Ingelman-Sundberg, M., Hagen, K. and Hultcrantz, R.: Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation. *J Hepatol* 1996, 25: 538-546.
166. Roh, H.-K., Dahl, M.-L., Johansson, I., Ingelman-Sundberg, M., Cha, Y.-N. and Bertilsson, L.: Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. *Pharmacogenetics*, 1996, 6: 441-447.
167. Clot, P., Albano, E., Eliasson, E., Tabone, M., Arico, S., Israel, Y., Moncada, C. and Ingelman-Sundberg, M.: Cytochrome P4502E1 (CYP2E1) hydroxyethyl radical adducts as the major antigenic determinants for autoantibody formation among alcoholics, 1996, *Gastroenterology*, 111: 206-216.
168. Nedelcheva, V., Persson, I., Johansson, I. and Ingelman-Sundberg, M.: Genetic polymorphism of human cytochrome P450 2E1. *Meth Enzymol*, 1996, 272: 218-225.
169. Johansson, I., Lundqvist, E., Dahl, M.-L. and Ingelman-Sundberg, M.: PCR-based genotyping for duplicated and deleted CYP2D6 genes. *Pharmacogenetics*, 1996, 6: 351-355.
170. Ingelman-Sundberg, M., Hagbjörk, A.-L., Ueng, Y.-F., Yamazaki, H. and Guengerich, F.P.: High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: Influence of membrane charge. *Biochem Biophys Res Commun*, 1996, 221: 318-315.
171. French, S.W., Morimoto, M., Reitz, R.C., Koop, D., Klopfenstein, B, Estes, K. Clot, P., Ingelman-Sundberg, M, and Albano, E.: Lipid peroxidation, CYP2E1 and arachidonic acid metabolism in alcoholic liver disease in rats. *J. Nutrition*, 1997, 127(5): 907-911.
172. Daly, A.K., Brockmöller, J. Broly, F., Eichelbaum, M., Evans, W.E., Gonzalez, F.J., Huang, J-D., Idle, J.R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer,

- U.A., Nebert, D.W., Steen, V.M., Wolf, C.R. and Zanger, U.M.: Nomenclature for human CYP2D6 alleles, *Pharmacogenetics*, 1996, 6: 193-201.
173. Neve, E., Eliasson, E., Pronzato, M.A., Albano, E., Marinari, U and Ingelman-Sundberg, M.: Enzyme-specific transport of rat liver cytochrome P450 to the Golgi apparatus, *Arch Biochem Biophys*, 1996, 333: 459-465.
 174. Persson, I., Aklillu, E., Rodrigues, F., Bertilsson, L. and Ingelman-Sundberg, M: S-Mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. *Pharmacogenetics*, 1996, 6: 521-526.
 175. Masimirembwa, C., Persson, I., Bertilsson, L., Hasler J. and Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. *Br J Clin Pharmacol*, 1996, 42: 713-719.
 176. Song B.J., Koop, D.R., Ingelman-Sundberg, M., Nanji, A.A. and Cederbaum A.I., Ethanol-inducible cytochrome P450 (CYP2E1): Biochemistry, molecular biology and clinical relevance: 1996 update. *Alcohol Clin Exp Res*, 1996, 20: 138A-146A.
 177. Thurman, R.G., Ingelman-Sundberg, M., Cederbaum, A.I., Fernandez-Checa, J.C., Kato, S., Yokoyama, H. and Tsukamoto, H.: Oxidative stress in alcoholic liver injury. *Alcohol Clin Exp Res*, 1996, 20: 162A-167A.
 178. Tindberg, N. and Ingelman-Sundberg, M. Expression, catalytic activity, and inducibility of cytochrome P450 2E1 (CYP2E1) in the rat central nervous system. *J. Neurochemistry*, 1996, 67: 2066-2073.
 179. Gouillon ZQ, Miyamoto K, Donohue TM, Wan YJ, French BA, Nagao Y, Fu P, Reitz RC, Hagbjork A, Yap C, Yuan QX, Ingelman-Sundberg M, French SW. Role of CYP2E1 in the pathogenesis of alcoholic liver disease: modifications by cAMP and ubiquitin-proteasome pathway. *Front Biosci*. 1999;4:A16-25.
 180. Clot, P., Parola, M., Bellomo, G., Dianzani, U., Carini, R., Tabone, M., Aricò, S., Ingelman-Sundberg, M. and Albano, E.: Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol. *Gastroenterology*, 1997, 113, 265-276.
 181. Schrenk, D., Orzechowski, A., Schwarz, L.R., Snyder, R., Burchell, B., Ingelman-Sundberg, M. and Bock, K.W.: Phase II metabolism of benzene. *Environ Health Perspect*, 1996, 104: 1183-1187.
 182. Masimirembwa, C., Hasler, J., Bertilsson, L., Johansson, I., Ekberg, O. and Ingelman-Sundberg, M.: Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. *Eur J Clin Pharmacol*, 1996, 51: 117-122.
 183. McLellan, R.A., Oscarson, M., Seidegård, J., Evans, D.A.P. and Ingelman-Sundberg, M: Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. *Pharmacogenetics*, 1997, 7: 187-191.
 184. Persson, I., Johansson, I. and Ingelman-Sundberg, M.: In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. *Biochem Biophys Res Commun*, 1997, 231: 227-230.

185. Zhukov, A., Hellman, U. and Ingelman-Sundberg, M.: Purification and characterization of hepsin from rat liver microsomes. *Biochim Biophys Acta*, 1997, 1337: 85-95.
186. Fang, C., Mkrtchian, S. and Ingelman-Sundberg, M.: Combination of direct DNA sequencing with degenerate primer-mediated PCR and 5'-/3'-RACE to screen novel cDNA sequences. *Biotechniques*, 1997, 23: 52-56.
187. Martini, R., Ingelman-Sundberg, M. And Murray M.: Pretranslational and posttranslational regulation of rat hepatic CYPs 3A2 and 2E1 by disulfiram. *Biochem Pharmacol*, 1997, 54: 1323-1329.
188. Weltman, M.D., Farrell, G.C., Hall, P., Ingelman-Sundberg, M. And Liddle, C.: Hepatic CYP2E1 is increased in patients with non-alcoholic steatohepatitis. *Hepatology*, 1998, 27: 128-133.
189. Lytton, S.D., Helander, A., Zhang-Gouillon, Z., Stokkeland, K., Bordone, R., Aricó, S., Albano, E., French, S.W. and Ingelman-Sundberg, M.: Autoantibodies against cytochromes P450s 2E1 and 3A in alcoholics. *Mol Pharmacol*, 55:223-233, 1999.
190. Zhukov, A. and Ingelman-Sundberg, M.: Selective fast degradation of cytochrome P450 2E1 in serum-deprived hepatoma cells by a mechanism sensitive to inhibitors of vesicular transport. *Eur J Biochem*, 1997, 247: 37-43.
191. Mkrtchian, S., Fang, C., Hellman, U. and Ingelman-Sundberg, M.: A stress-inducible endoplasmic reticulum protein, ERp29. *Eur J Biochem*, 1998, 251: 304-313.
192. Oscarson, M., Hidestrand, M., Johansson, I., and Ingelman-Sundberg, M.: A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. *Mol Pharmacol*, 1997, 52: 1034-1040.
193. McLellan, R., Oscarson, M., Alexandrie, A.-K., Seidegård, J., Evans, D.A.P., Rannug, A. and Ingelman-Sundberg, M.: Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene causing ultrarapid enzyme activity. *Mol Pharmacol*, 1997, 52:958-965.
194. Parola, M., Robino, G., Bordone, R., Leonarduzzi, G., Casini, A., Pinzani, M., Neve, E., Bellomo, G., Dianzani MU., Ingelman-Sundberg M. and Albano, E.: Detection of cytochrome P450A (CYP3A) in human hepatic stellate cells, *Biochem Biophys Res Commun*, 1997, 238: 420-424.
195. Zhukov, A. and Ingelman-Sundberg, M: Relationship between cytochrome P450 catalytic cycling and stability: Fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase, *Biochem J.*, 1999, 340: 453-458
196. Albano, E., French, S. and Ingelman-Sundberg, M.: Cytochrome P4502E1 and immune reactions associated to alcoholic liver disease. *Alcoholism. Exp Clin Res*, 1998, 22: 740-742.
197. Ingelman-Sundberg, M., Lytton, S. and Albano, E.: Role of cytochrome P450 enzymes in alcohol liver disease pathogenesis. *Alcoholism. Exp Clin Res*, 1998, 22: 739-740.
198. Fang, C., Lindros, KO., Badger, TM., Ronis, MJJ. and Ingelman-Sundberg, M., Zonated expression of cytokines in rat liver: Effect of chronic ethanol and the cytochrome P4502E1 inhibitor chlormethiazole. *Hepatology*, 1998, 27: 1304-1310.

199. Bathum, L., Johansson, I., Ingelman-Sundberg, M., Hørder, M. and Brøsen, K: Ultrarapid metabolism of sparteine: Frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by RFLP and long PCR. 1998, *Pharmacogenetics*, 1998, 8: 119-123.
200. Korourian, S., Hakkak, R., Ronis, M.j.j., Shelnut, S.R., Waldron, J., Ingelman-Sundberg, M. and Badger, T.M. Diet and risk of ethanol-induced hepatotoxicity: Carbohydrate-fat relationships. *Toxicol Sci.* 47: 110-117, 1999.
201. French, S., Zhang-Gouillon, ZQ. and Ingelman-Sundberg, M.: The role of CYP2E1 induction by ethanol in the pathogenesis of alcoholic liver diseases as determined by inhibitors of CYP2E1 transcription and post translation modulating factors. 1998, *Alcoholism. Exp Clin Res*, 1998, 22:738-739.
202. Ingelman-Sundberg, M.; The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics. *Arch Toxicol Suppl*, 1997, 19:3-13.
203. Badger TM. Korourian S. Hakkak R. Ronis MJJ. Shelnut SR. Ingelman-Sundberg M. Waldron J. Carbohydrate deficiency as a possible factor in ethanol-induced hepatic necrosis. *Alc Clin Exp Res*, 1998, 22: 742.
204. Nedelcheva V, Gut I, Soucek P, Tichavska B, Tynkova L, Mraz J, Guengerich FP, Ingelman-Sundberg M Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression *Arch Toxicol* 1999, 73:33-40
205. Ingelman-Sundberg, M. and Oscarson, M.: Prediction of human drug metabolism using in vitro systems, *Clin Pharmacology*, 1998, 16: 7-15.
206. Ingelman-Sundberg, M.: Duplication, multiduplication and amplification of genes encoding drug metabolising enzymes. Evolutionary, toxicological and clinical pharmacological aspects, 1998, *Drug Metab Rev*, 31:449-459.
207. Nebert, D.W, Ingelman-Sundberg, M. and Daly, A.K: Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drugmetabolizing enzyme genes, their functional importance, and nomenclature issues, 1999, *Drug Met Rev* 31: 467-487.
208. Backlund, M., Weidolf, L. and Ingelman-Sundberg, M.: Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells, 1999, *Eur J Biochem* 261:66-71.
209. Bernal, M.L., Sinues, B., Johansson, I., McLellan, R., Dahl, M-L., Ingelman-Sundberg, M. and Bertilsson, L.: Ten percent of North Spanish subjects carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine, 1999, *Pharmacogenetics*, 9:657-60.
210. Wennerholm, A., Johansson, I., Massele, A.Y., Sayi, J., Alm, C., Aden Abdi, Y., Dahl, M-L., Ingelman-Sundberg, M., Bertilsson, L. and Gustafsson, L.: Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. 1999, *Pharmacogenetics*, 9:707-14
211. Mkrtchian, S., Baryshev, M., Matvijenko, O., Sharipo, A., Sandalova, T., Schneider, G. and Ingelman-Sundberg, M.: Oligomerization properties of Erp29, an endoplasmic reticulum stress protein, *FEBS Letters*, 1998, 431: 322-326.

212. Simi, A and Ingelman-Sundberg, M.: Posttranslational inhibition of cytochrome P450 2E1 expression by chlormethiazole in Fao hepatoma cells. *J Pharm Exp Ther*, 1999, 289:847-852.
213. Ingelman-Sundberg M. Functional consequences of polymorphism of xenobiotic metabolising enzymes, *Toxicology Letters*, 1998, 103: 155-160.
214. Yasar U. Eliasson E. Dahl ML. Johansson I. Ingelman-Sundberg M. Sjoqvist F. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population, *Biochem Biophys Res Commun*, 1999, 254: 628-631.
215. Oscarson M. Gullsten H. Rautio A. Bernal ML. Sinues B. Dahl ML. Stengard JH. Pelkonen O. Raunio H. Ingelman-Sundberg M. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. *FEBS Lett*, 1998, 438: 201-205.
216. Persson I, Johansson I, Lou YC, Yue QY, Duan LS, Bertilsson L, Ingelman-Sundberg M Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients, *Int J Cancer*, 1999, 81: 325-329.
217. Jarvelainen HA, Fang C, Ingelman-Sundberg M, Lindros KO: Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and pro-inflammatory and anti-inflammatory cytokines, *Hepatology*, 1999, 29:1503-1510.
218. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML, Sinues B, Hirvonen A, Raunio H, Pelkonen O, Ingelman-Sundberg M Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population, *FEBS Lett*, 1999, 448:105-110.
219. Raucy JL, Ingelman-Sundberg M, Carpenter S, Rannug A, Rane A, Franklin M, Romkes M Drug metabolizing enzymes in lymphocytes, *J Biochem Mol Toxicol* 1999, 13: 223-226.
220. Westlind A, Lofberg L, Tindberg N, Andersson TB, and Ingelman-Sundberg M: Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5'-Upstream Regulatory Region. *Biochem Biophys Res Commun*, 1999, 259: 201-205.
221. Albano E, French S W, Ingelman-Sundberg M: Hydroxyethyl radicals in ethanol hepatotoxicity, *Front Biosci*, 1999, 4:533-540.
222. Ingelman-Sundberg M, Oscarson M, McLellan R A: Polymorphic human cytochrome P450 enzymes: an opportunity for individualised drug treatment, *Trends Pharmacol Sci*, 1999, 20: 342-349.
223. Ingelman-Sundberg M: Ethanol- inducible cytochrome P4502E1, Roles in Alcohol Toxicity, *Arqui Med*, 1998, 12: 106-108.
224. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M: Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes. Identification of a polymorphic repeat in the human gene. *Biochem. Biophys. Res. Commun.*, 1999, 263: 286-293.
225. Chen GF, Ronis MJ, Ingelman-Sundberg M, Badger TM: Hormonal regulation of microsomal cytochrome P4502E1 and P450 reductase in rat liver and kidney. *Xenobiotica*, 1999, 29: 437-451.
226. Gouillon ZQ, Miyamoto K, Donohue T, Wan YJ, French B, Nagao Y, Fu P, Reitz R, Hagbjörk A, Yap C, Yuan Q, Ingelman-Sundberg M, French S: Role of CYP2E1 in the

- pathogenesis of alcoholic liver disease: modifications by cAMP and ubiquitin-proteasome pathway. *Front Biosci* 1999, 4: A16-25.
227. Oscarson M, McLellan RA, Gullstén H, Agúndez JAG, Benítez J, Rautio A, Raunio H, Pelkonen O, Ingelman-Sundberg M: Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. *FEBS Lett*, 1999, 460: 321-327.
 228. Neve EPA, Ingelman-Sundberg M: A soluble NH₂-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria. *FEBS Lett*, 1999, 460: 309-314.
 229. Järveläinen HA, Fang C, Ingelman-Sundberg M, Lukkari T, Sippel H, Lindros KO: Kupffer cell inactivation alleviates rat liver ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver, *J Hepatol*, 2000, 32: 900-910.
 230. Simi A, Ingelman-Sundberg M, Tindberg N: Neuroprotective agent chlormethiazole attenuates c-fos, c-jun and AP-1 activation through inhibition of p38 MAP kinase, *J Cereb Blood F Met*, 2000, 20:1077-1088.
 231. Longo V, Ingelman-Sundberg M, Amato G, Salvetti A, Gervasi PG: Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa. *Biochem Pharmacol* 2000, 59:1425-1432.
 232. Gouillon Z-Q, Lucas D, Li J, Hagbjork AL, French BA, Fu P, Ingelman-Sundberg M, Donohue JrTM, French SW: Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole, *Proc Exp Soc Med*, 2000, 224: 302-308.
 233. Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW: Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. *Pharmacogenetics*, 2000, 10: 91-93.
 234. Neve EPA, Ingelman-Sundberg M: Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane. 2000, *J. Biol. Chem*, 275:17130-17135.
 235. McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, Ingelman-Sundberg M: Characterization and functional analysis of two common human cytochrome P450 1B1 variants, *Arch Biochem Biophys*, 2000, 378:175-181.
 236. Bylund J, Hidestrand M, Ingelman-Sundberg M, Oliw EH: CYP4F8 of human seminal vesicles is a prominent 19-hydroxylase of prostaglandin endoperoxides, *J Biol Chem*, 2000, 275: 1844-1849.
 237. Badger TM, Hoog J-O, Svensson S, McGehee RE, Fang C, Ronis MJJ, Ingelman-Sundberg M: Cyclic expression of class I alcohol dehydrogenase in male rats treated with ethanol. *Biochem Bioph Res Commun*, 2000, 274: 684-688.
 238. Bardag-Gorce F, Yuan QX, Li J, French BA, Fang C, Ingelman-Sundberg M, French SW. The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. *Biochem Biophys Res Commun*. 2000, 279: 23-29.
 239. Werlinder V, Backlund M, Zhukov A, Ingelman-Sundberg M: Transcriptional and posttranslational regulation of CYP1A1 by primaquine. *J Pharm Exp Ther*, 2001, 297: 206-214.

240. Rylander, T., Neve, E.P.A., Ingelman-Sundberg M. and Oscarson, M.: Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1) *Biochem Biophys Res Commun*, 2001, 281: 529-535.
241. Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T.B., Ingelman-Sundberg, M. and Oscarson, M.: Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. *Biochem Biophys Res Commun*, 2001, 281:1349-55.
242. Ingelman-Sundberg, M.: Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. *Mutation research*, 2001, 482: 11-19..
243. Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L.L. and Ingelman-Sundberg, M.: Characterization of a new CYP2D6 allele (CYP2D6*29) commonly present in a black Tanzanian population causing reduced catalytic activity, *Pharmacogenetics*, 2001, 11: 417-427..
244. Andersson, T.B., Sjöberg, H., Hoffman, K.-J., Boobis, A.R., Watts, P., Edwards RJ, Lake BG., Price R.J., Renwic, A.B., Gómez-Lechón, M.J., Castell, J.V., Ingelman-Sundberg, M., Hidestrand, M., Goldfarb, P., Lewis, D., Corcos, L., Guillouzo, A., Taavitsainen, P. and Pelkonen, O.: An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of Almokalant, *Drug Met Disp*, 2001, 29:712-20.
245. Neve EP, Ingelman-Sundberg M.: Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1). *J Biol Chem*. 2001, 276:11317-22.
246. Pitarque, M., von Richter, O., Oke, B., Berkkan, H, Oscarson, M and Ingelman-Sundberg M.: Identification of a Single Nucleotide Polymorphism in the TATA box of the CYP2A6 Gene: Impairment of its Promoter Activity. *Biochem Biophys Res Commun*, 2001, 284: 455-460.
247. Scordo, M.G., Aklillu, E., Yasar, U., Dahl, M.-L., Spina, E., and Ingelman-Sundberg, M.: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a Black-African population. *Br J Clin Pharm*, 2001, 52: 447-450.
248. Pelkonen, O., Myllynen, P., Taavitsainen, P., Boobis, A.R., Watts, P., Lake, B.G., Price, R.J., Renwick, A.B., Gómez-Lechón, M.-J., Castell, J.V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S., Lewis, D.F.V.: Carbamazepine: a “blind” assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. 2001, *Xenobiotica*, 31:321-343.
249. Yasar, Ü., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman-Sundberg, M., Dahl, M.-L., Eliasson, E.: The role of CYP2C9 polymorphism in losartan oxidation. 2001, *Drug Met Disp*, 29: 1051-1056.
250. Liepinsh, E., Baryshev, M., Sharipo, A., Ingelman-Sundberg, M., Otting, G., Mkrtchian, S.: Thioredoxin fold as a homodimerization module in the putative chaperone ERp29: NMR structures of the domains and experimental model of the 54 kDa homodimer. *Structure*, 2001, 9: 457-471.

251. Hosseinpour F, Hidestrand M, Ingelman-Sundberg M, Wikvall K. The Importance of Residues in Substrate Recognition Site 3 for the Catalytic Function of CYP2D25 (Vitamin D 25-Hydroxylase). *Biochem Biophys Res Commun*. 2001; 288:1059-63.
252. Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M. CYP2B6 and Cyp2c19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of parkinson's disease, as revealed from experiments with recombinant enzymes. *Drug Metab Dispos*. 2001; 29:1480-4.
253. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW. Human Cytochrome P-450 (CYP) Genes: A Web Page for the Nomenclature of Alleles. *Cancer Epidemiol Biomarkers Prev*. 2001; 10:1307-8.
254. Garte S, Ingelman-Sundberg M, ... Persson I, ... Vineis P, Yu MC, Taioli E. Metabolic gene polymorphism frequencies in control populations. *Cancer Epidemiol Biomarkers Prev*. 2001; 10:1239-48.
255. Hedberg JJ, Backlund M, Stromberg P, Lonn S, Dahl ML, Ingelman- Sundberg M, Hoog JO. Functional polymorphism in the alcohol dehydrogenase 3 (ADH3) promoter. *Pharmacogenetics*. 2001; 11:815-24.
256. Evans WE, Ingelman-Sundberg M. Resequencing the sulfotransferase SULT1 gene provides new insights, while illuminating challenges that lie ahead for pharmacogenomics. *Pharmacogenetics*. 2001; 11:745-6.
257. Ingelman-Sundberg M, Evans WE. Unravelling the functional genomics of the human CYP2D6 gene locus. *Pharmacogenetics*. 2001; 11:553-4.
258. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. *J Intern Med*. 2001; 250:186-200..
259. Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, Brockmoller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M, Kremers P, LeMarchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stucker I, To-Figueras J, Brennan P, Taioli E. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. *Carcinogenesis*. 2002; 23:1343-50.
260. Bardag-Gorce F, French BA, Li J, Riley NE, Yuan QX, Valinluck V, Fu P, Ingelman-Sundberg M, Yoon S, French SW. The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats. *Gastroenterology*. 2002; 123:325-35.
261. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. *Toxicology*. 2002;181-182:447-52..
262. Gavrilovich Zgoda V, Arison B, Mkrtchian S, Ingelman-Sundberg M, Almira Correia M. Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a role for glutathione and GRP94 in the heme-protein assembly. *Arch Biochem Biophys*. 2002; 408:58-68.
263. Ingelman-Sundberg M, Oscarson M. Human CYP allele database: submission criteria procedures and objectives. *Methods Enzymol*. 2002; 357:28-36.

264. Simi A, Porsmyr-Palmertz M, Hjerten A, Ingelman-Sundberg M, Tindberg N. The neuroprotective agents chlomethiazole and SB203580 inhibit IL-1 β signalling but not its biosynthesis in rat cortical glial cells. *J Neurochem.* 2002; 83:727-37.
265. Oscarson M, McLellan RA, Asp V, Ledesma M, Ruiz ML, Sinues B, Rautio A, Ingelman-Sundberg M. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. *Hum Mutat.* 2002; 20:275-83.
266. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. *Pharmacogenetics.* 2002; 12:375-83.
267. Oscarson M, Ingelman-Sundberg M. CYPalleles: A Web Page for Nomenclature of Human Cytochrome P450 Alleles. *Drug Metab Pharmacokinet.* 2002; 17:491-5.
268. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L, Taioli E. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. *Biomarkers.* 2002; 7:230-41..
269. Bardag-Gorce F, French BA, Li J, Riley NE, Yuan QX, Valinluck V, Fu P, Ingelman-Sundberg M, Yoon S, French SW. The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats. *Gastroenterology.* 2002; 123:325-35.
270. Lytton SD, Berg U, Nemeth A, Ingelman-Sundberg M. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs. *Clin Exp Immunol.* 2002; 127:293-302.
271. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. *Mol Pharmacol.* 2002; 61:586-94.
272. Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, Bertilsson L, Hasler J, Gustafsson LL. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. *Clin Pharmacol Ther.* 2002; 71:77-88.
273. Neve EP, Hidestrand M, Ingelman-Sundberg M. Identification of sequences responsible for intracellular targeting and membrane binding of rat CYP2E1 in yeast. *Biochemistry.* 2003; 42:14566-75.
274. Tamasi V, Hazai E, Porsmyr-Palmertz M, Ingelman-Sundberg M, Vereczkey L, Monostory K. GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4-yl)propionic acid] antagonist, is a CYP2E1 inducer. *Drug Metab Dispos.* 2003;31(11):1310-4.
275. Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. Xanthine oxidase activity is influenced by environmental factors in Ethiopians. *Eur J Clin Pharmacol.* 2003; 59:533-6.
276. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. *Mol Pharmacol.* 2003; 64:659-69.

277. Salonen JS, Nyman L, Boobis AR, Edwards RJ, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF, Taavitsainen P, Pelkonen O. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. *Drug Metab Dispos.* 2003; 31:1093-102.
278. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stucker I, Sugimura H, Taioli E. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). *Cancer Causes Control.* 2003; 14:339-46.
279. Rylander-Rudqvist T, Wedren S, Granath F, Humphreys K, Ahlberg S, Weiderpass E, Oscarson M, Ingelman-Sundberg M, Persson I. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. *Carcinogenesis.* 2003; 24:1533-9.
280. Westlind-Johnsson A, Malmbo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. *Drug Metab Dispos.* 2003; 31:755-61.
281. Wedren S, Rudqvist TR, Granath F, Weiderpass E, Ingelman-Sundberg M, Persson I, Magnusson C. Catechol-O-methyltransferase gene polymorphism and postmenopausal breast cancer risk. *Carcinogenesis.* 2003; 24:681-7.
282. Rodriguez-Antona C, Bort R, Jover R, Tindberg N, Ingelman-Sundberg M, Gomez-Lechon MJ, Castell JV. Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. *Mol Pharmacol.* 2003; 63:1180-9.
283. Aklilu E, Hidestrand M, Ingelman-Sundberg M, Malmbo S, Westlind A. Recent Progress in Drug Metabolism Research. *Drug News Perspect.* 2002; 15:528-534.
284. Badger TM, Ronis MJ, Seitz HK, Albano E, Ingelman-Sundberg M, Lieber CS. Alcohol metabolism: role in toxicity and carcinogenesis. *Alcohol Clin Exp Res.* 2003; 27:336-47.
285. Hakkola J, Hu Y, Ingelman-Sundberg M. Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. *J Pharmacol Exp Ther.* 2003; 304:1048-54.
286. Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Ingelman-Sundberg M, Kihara M, Kiyohara C, Kremers P, Le Marchand L, Ohshima S, Pastorelli R, Rannug A, Romkes M, Schoket B, Shields P, Strange RC, Stucker I, Sugimura H, Garte S, Gaspari L, Taioli E. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. *Int J Cancer.* 2003; 104:650-7.
287. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. *Trends Pharmacol Sci.* 2004; 25:193-200.
288. Ronis MJ, Hakkak R, Korourian S, Albano E, Yoon S, Ingelman-Sundberg M, Lindros KO, Badger TM. Alcoholic liver disease in rats fed ethanol as part of oral or intragastric low-carbohydrate liquid diets. *Exp Biol Med.* 2004; 229:351-60.

289. Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. *Biochem Pharmacol.* 2004; 67:1389-97.
290. Butura A, Johansson I, Nilsson K, Warngard L, Ingelman-Sundberg M, Schuppe-Koistinen I. Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling. *Biochem Pharmacol.* 2004; 67:1249-58.
291. Karlgren M, Backlund M, Johansson I, Oscarson M, Ingelman-Sundberg M. Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. *Biochem Biophys Res Commun.* 2004; 315:679-85.
292. Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. *Hum Mutat.* 2004; 23:258-66.
293. Backlund M, Ingelman-Sundberg M. Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. *Mol Pharmacol.* 2004; 65:416-25.
294. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. *Naunyn Schmiedebergs Arch Pharmacol.* 2004; 369:89-104.
295. Gomez A, Ingelman-Sundberg M, Johansson I, Karlgren M, Rodriguez-Antona C, Sim SC. New approaches and applications in chemical biology. *Drug News Perspect.* 2004 17:594-605.
296. Vidali M, Hidestrand M, Eliasson E, Mottaran E, Reale E, Rolla R, Occhino G, Albano E, Ingelman-Sundberg M. Use of molecular simulation for mapping conformational CYP2E1 epitopes. *J Biol Chem.* 2004; 279:50949-55.
297. Rylander-Rudqvist T, Wedren S, Jonasdottir G, Ahlberg S, Weiderpass E, Persson I, Ingelman-Sundberg M. Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2004; 13:1515-20.
298. von Richter O, Pitarque M, Rodriguez-Antona C, Testa A, Mantovani R, Oscarson M, Ingelman-Sundberg M. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). *Pharmacogenetics.* 2004; 14:369-79.
299. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. *Am J Clin Nutr.* 2004; 79:935-45..
300. Ronis MJ, Korourian S, Yoon S, Ingelman-Sundberg M, Albano E, Lindros KO, Badger TM. Lack of sexual dimorphism in alcohol-induced liver damage (ALD) in rats treated chronically with ethanol-containing low carbohydrate diets: The role of ethanol metabolism and endotoxin. *Life Sci.* 2004; 75:469-83.
301. Smits KM, Benhamou S, Garte S, Weijenberg MP, Alamanos Y, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Boffetta P, Bouchardy C, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Coutelle C, Daly AK, Muzi G, Dolzan V, Duzhak TG, Farker K, Golka K, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Katoh T, Kihara M, Ono-Kihara M, Kim H, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, London S,

- Manni JJ, Maugard CM, Morgan GJ, Morita S, Nazar-Stewart V, Kristensen VN, Oda Y, Parl FF, Peters WH, Rannug A, Rebbeck T, Pinto LF, Risch A, Romkes M, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnett D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Zheng W, Pedotti P, Taioli E. Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. *Int J Cancer*. 2004; 110:266-70.
302. Pitarque M, Rodriguez-Antona C, Oscarson M, Ingelman-Sundberg M. Transcriptional regulation of the human cytochrome P450 2A6 (CYP2A6) gene. *J Pharmacol Exp Ther*. 2005; **313**:814-22
 303. Andersson S, Hofmann Y, Nordling A, Li XQ, Nivelius S, Andersson TB, Ingelman-Sundberg M, Johansson I. Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. *Drug Metab Dispos*. 2005; **33**:570-8.
 304. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J*. 2005; **5**:6-13.
 305. Backlund M, Ingelman-Sundberg M. Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. *Cell Signal*. 2005; **17**:39-48.
 306. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. *Philos Trans R Soc Lond B Biol Sci*. 2005; **360**:1563-70.
 307. Ronis MJ, Butura A, Sampey BP, Shankar K, Prior RL, Korourian S, Albano E, Ingelman-Sundberg M, Petersen DR, Badger TM. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. *Free Radic Biol Med*. 2005; **39**:619-630.
 308. Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. *Pharmacogenet Genomics*. 2005; **15**:625-31.
 309. Raimondi S, Boffetta P, Anttila S, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Dragani TA, Garte S, Gsur A, Haidinger G, Hirvonen A, Ingelman-Sundberg M, Kalina I, Lan Q, Leoni VP, Marchand LL, London SJ, Neri M, Povey AC, Rannug A, Reszka E, Ryberg D, Risch A, Romkes M, Ruano-Ravina A, Schoket B, Spinola M, Sugimura H, Wu X, Taioli E. Metabolic gene polymorphisms and lung cancer risk in non-smokers An update of the GSEC study. *Mutat Res*. 2005; **592**:45-57
 310. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. *Toxicol Appl Pharmacol*. 2005 **207**:52-6
 311. Karlgren M, Miura SI, Ingelman-Sundberg M. Novel extrahepatic cytochrome P450s. *Toxicol Appl Pharmacol*. 2005; **207**:57-61
 312. Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. *Cancer Res*. 2005; **65**:5105-11.
 313. Rodriguez-Antona C, Axelson M, Otter C, Rane A, Ingelman-Sundberg M. A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. *J Biol Chem*. 2005 ; **280**:28324-31.
 314. Rodriguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. *Clin Pharmacol Ther*. 2005; **77**:259-70.

315. Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M, Hartung T, Coecke S. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. *Toxicol In Vitro*. 2005; **19**:621-9.
316. Simi A, Edling Y, Ingelman-Sundberg M, Tindberg N. Activation of c-fos by lipopolysaccharide in glial cells via p38 mitogen-activated protein kinase-dependent activation of serum or cyclic AMP/calcium response element. *J Neurochem*. 2005; **92**:915-24.
317. Ingelman-Sundberg M, Sim SC, Nebert DW. Coffee, myocardial infarction, and CYP nomenclature. *JAMA*. 2006; **296**:764-5;
318. Sim SC, Ingelman-Sundberg M. The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. *Methods Mol Biol*. 2006; **320**:183-91.
319. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldana SN, Sorter M, Vinks AA, Nassr N, von Richter O, Jin L, Nebert DW. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. *Pharmacogenet Genomics*. 2006; **16**:359-67.
320. Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech K, Ingelman-Sundberg M, von Richter O. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. *Clin Pharmacol Ther*. 2006; **79**:339-49.
321. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. *Oncogene*. 2006; **25**:1679-91.
322. Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, Elaut G, Elettì B, Freidig A, Gennari A, Gherzi-Egea JF, Guillouzo A, Hartung T, Hoet P, Ingelman-Sundberg M, Munn S, Janssens W, Ladstetter B, Leahy D, Long A, Meneguz A, Monshouwer M, Morath S, Nagelkerke F, Pelkonen O, Ponti J, Prieto P, Richert L, Sabbioni E, Schaack B, Steiling W, Testai E, Vericat JA, Worth A. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. *Altern Lab Anim*. 2006; **34**:49-84.
323. Wang J, Sönnernborg A, Rane A, Josephson F, Lundgren S, Ståhle L, Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. *Pharmacogenet Genomics*. 2006; **16**:191-8.
324. Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E, Bernal ML, Ramón y Cajal S, Johansson I, Ingelman-Sundberg M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. *Biochem Biophys Res Commun*. 2006; **341**:451-8.
325. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clin Pharmacol Ther*. 2006; **79**:103-13.
326. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. *Annu Rev Med*. 2006; **57**:119-37.
327. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. *Pharmacol Ther*. 2007; **116**:496-526.
328. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M. Expression of CYP2W1 in colon tumors: regulation by gene methylation. *Pharmacogenomics*. 2007; **8**:1315-1325.

329. Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. *Pharmacogenomics J*. 2007; **8**:268-77.
330. Söderdahl T, Küppers-Munther B, Edsbacke J, Andersson TB, Björquist P, Cotgreave I, Jernström B, Ingelman-Sundberg M, Johansson I. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. *Biochem Pharmacol*. 2007; **74**:496-503.
331. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. *Eur J Clin Pharmacol*. 2007; **63**:537-46.
332. Arakelyan KP, Sahakyan YA, Hayrapetyan LR, Khudaverdyan DN, Ingelman-Sundberg M, Mkrtchian S, Ter-Markosyan AS. Calcium-regulating peptide hormones and blood electrolytic balance in chronic heart failure. *Regul Pept*. 2007; **142**:95-100. Epub 2007 Feb 16.
333. Herman D, Dolzan V, Ingelman-Sundberg M. Characterization of the novel defective CYP2C9*24 allele. *Drug Metab Dispos*. 2007; **35**:831-4.
334. Afzelius L, Ingelman-Sundberg M, Karlgren M, Rodríguez-Antona C. Novel aspects of drug metabolism and transport. *Drug News Perspect*. 2006; **19**:637-51.
335. Karlgren M, Ingelman-Sundberg M. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. *Expert Opin Ther Targets*. 2007; **11**:61-7.
336. Edling Y, Ingelman-Sundberg M, Simi A. Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. *Glia*. 2007; **55**:328-40.
337. Ek M, Söderdahl T, Küppers-Munther B, Edsbacke J, Andersson TB, Björquist P, Cotgreave I, Jernström B, Ingelman-Sundberg M, Johansson I. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. *Biochem Pharmacol*. 2007; **74**:496-503.
338. Ingelman-Sundberg M, Sim SC, Gomez A, Rodríguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoeconomic and clinical aspects. *Pharmacol Ther*. 2007; **116**:496-526. Epub 2007 Oct 9
339. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M. Expression of CYP2W1 in colon tumors: regulation by gene methylation. *Pharmacogenomics*. 2007; **8**:1315-25.
340. Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. *Pharmacogenomics J*. 2008; **8**:268-77. Epub 2007 Oct 9.
341. Ek M, Söderdahl T, Küppers-Munther B, Edsbacke J, Andersson TB, Björquist P, Cotgreave I, Jernström B, Ingelman-Sundberg M, Johansson I. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. *Biochem Pharmacol*. 2007; **74**:496-503. Epub 2007 May 17.
342. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. *Eur J Clin Pharmacol*. 2007; **63**:537-46. Epub 2007 Mar 17.
343. Herman D, Dolzan V, Ingelman-Sundberg M. Characterization of the novel defective CYP2C9*24 allele. *Drug Metab Dispos*. 2007; **35**:831-4. Epub 2007 Mar 1.

344. Johansson I, Ingelman-Sundberg M. Current research in drug metabolism, drug transport and drug development. *Drug News Perspect.* 2008;21:518-28.
345. Butura A, Nilsson K, Morgan K, Morgan TR, French SW, Johansson I, Schuppe-Koistinen I, Ingelman-Sundberg M. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. *J Hepatol.* 2009;50:572-83. Epub 2008 Dec 25.
346. Edler D, Stenstedt K, Ohrling K, Hallström M, Karlgren M, Ingelman-Sundberg M, Ragnhammar P. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - a pilot study. *Eur J Cancer.* 2009;45:705-12. Epub 2008 Dec 30.
347. Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC, Bertilsson L, Ingelman-Sundberg M, Eliasson E. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. *Eur J Clin Pharmacol.* 2008; 64:1175-9. Epub 2008 Jul 25.
348. Edling Y, Sivertsson L, Andersson TB, Porsmyr-Palmertz M, Ingelman-Sundberg M. Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. *Toxicol In Vitro.* 2008; 22:1588-94. Epub 2008 Jul 2.
349. Neve EP, Ingelman-Sundberg M. Intracellular transport and localization of microsomal cytochrome P450. *Anal Bioanal Chem.* 2008;392:1075-84. Epub 2008 Jun 8.
350. Chavarria-Soley G, Sticht H, Aklillu E, Ingelman-Sundberg M, Pasutto F, Reis A, Rautenstrauss B. Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. *Hum Mutat.* 2008;29:1147-53.
351. Lee KM, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M, Kiyohara C, Min S, Lan Q, Le Marchand L, Lin P, Lung ML, Pinarbasi H, Pisani P, Srivatanakul P, Seow A, Sugimura H, Tokudome S, Yokota J, Taioli E. CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. *Cancer Epidemiol Biomarkers Prev.* 2008;17:1120-6. Epub 2008 May 7.
352. Ronis MJ, Butura A, Korourian S, Shankar K, Simpson P, Badeaux J, Albano E, Ingelman-Sundberg M, Badger TM. Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. *Exp Biol Med (Maywood).* 2008;233:344-55.
353. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. *Br J Clin Pharmacol.* 2008;65:767-74. Epub 2008 Feb 20.
354. Löfgren S, Baldwin RM, Hiratsuka M, Lindqvist A, Carlberg A, Sim SC, Schülke M, Snait M, Edenro A, Fransson-Steen R, Terelius Y, Ingelman-Sundberg M. Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. *Drug Metab Dispos.* 2008; 36:955-62. Epub 2008 Feb 14.
355. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. *N Engl J Med.* 2008;358:637-9.
356. Johansson I, Ingelman-Sundberg M. CNVs of human genes and their implication in pharmacogenetics. *Cytogenet Genome Res.* 2008;123:195-204. Epub 2009 Mar 11.
357. Mwinyi J, Nekvindová J, Cavaco I, Hofmann Y, Pedersen RS, Landman E, Mkrtchian S, Ingelman-Sundberg M. New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4. *Drug Metab Dispos.* 2010; 38:415-21. Epub 2009 Dec 7.

358. Edling Y, Sivertsson LK, Butura A, Ingelman-Sundberg M, Ek M. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. *Toxicol In Vitro*. 2009; 23:1387-95. Epub 2009 Jul 23.
359. Gomez A, Ingelman-Sundberg M. Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. *Pharmacogenomics*. 2009; 10:1067-76.
360. Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, Ding X, Wolf CR, Flück CE, Pandey AV, Henderson CJ, Porter TD, Daly AK, Nebert DW, Ingelman-Sundberg M. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. *Pharmacogenet Genomics*. 2009; 19:565-6.
361. Dutheil F, Dauchy S, Diry M, Szadovitch V, Cloarec O, Mellottée L, Bièche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Declèves X, Duyckaerts C, Lorient MA. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. *Drug Metab Dispos*. 2009;37:1528-38.
362. Huynh L, Masereeuw R, Friedberg T, Ingelman-Sundberg M, Manivet P. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: Beyond the reduction of animal model use. *Drug Discov Today*. 2009; 14:401-5.
363. Löfgren S, Baldwin RM, Carlerös M, Terelius Y, Fransson-Steen R, Mwinyi J, Waxman DJ, Ingelman-Sundberg M. Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. *Drug Metab Dispos*. 2009;37:1505-12.
364. Ghotbi R, Gomez A, Milani L, Tybring G, Syvänen AC, Bertilsson L, Ingelman-Sundberg M, Aklillu E. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. *Pharmacogenomics J*. 2009;9:208-17.
365. Gomez A, Ingelman-Sundberg M. Pharmacoeugenetics: its role in interindividual differences in drug response. *Clin Pharmacol Ther*. 2009;85:426-30.
366. Sutti, S, Vidali, M., Mombello, C, Sartori, M., Ingelman-Sundberg M and Albano. E. Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: possible role for molecular mimicry. *J. Hepatol*. 2010, 53:431-438
367. Ingelman-Sundberg M and Sim SC. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. *Biochem Biophys Res Commun*. 2010, 396:90-94 (KI 200 anniversary)
368. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, Brøsen K, Ingelman-Sundberg M. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. *Eur J Clin Pharmacol*. 2010 ;66:1199-205
369. Kotsovolou O, Ingelman-Sundberg M, Lang MA, Marselos M, Overstreet DH, Papadopoulou-Daifoti Z, Johanson I, Fotopoulos A, Konstandi M. Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010; 34:1075-84. Epub 2010 Jun 4.
370. Pasutto F, Chavarria-Soley G, Mardin CY, Michels-Rautenstrauss K, Ingelman-Sundberg M, Fernández-Martínez L, Weber BH, Rautenstrauss B, Reis A. Heterozygous loss-of-function variants in CYP1B1 predispose to primary open-angle glaucoma. *Invest Ophthalmol Vis Sci*. 2010; 51:249-54. Epub 2009 Jul 30.
371. Sim SC, Nordin L, Andersson TM, Virding S, Olsson M, Pedersen NL, and Ingelman-Sundberg M: Association between CYP2C19 polymorphism and depressive symptoms. *Am J Med Genet B Neuropsychiatr Genet*. 2010 153B:1160-6.

372. Andersson, TB, and Ingelman-Sundberg M., Livers cells derived from Human embryonic stem cells. Progress and potential use in ADMET applications. *Drug Disc Today: Technologies* 2010; 4, in press
373. Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. *Eur J Clin Pharmacol.* 2010 ;**66**:871-7
374. Sim SC, and Ingelman-Sundberg M, The Human Cytochrome P450 (CYP) Allele Nomenclature Website – a peer-reviewed database of CYP variants and their associated effects. *Human Genomics* 2010; 4:278-81.
375. Sivertsson L, Ek M, Darnell M, Edebert I, Ingelman-Sundberg M, Neve EP. CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells. *Drug Metab Dispos.* 2010;38:995-1002.
376. Mwinyi, J., Hofmann Y, Steen Pedersen R., Nekvindova J., Cavaco I. Mkrtchian S. and Ingelman-Sundberg M: The transcription factor GATA-4 regulates cytochrome P450C19 gene expression. *Life Sci.* 2010, 86:699-706
377. Neve EP, Ingelman-Sundberg M. .Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. *Curr Opin Drug Discov Devel.* 2010; 13:78-85.
378. Brolén G, Sivertsson L, Björquist P, Eriksson G, Ek M, Semb H, Johansson I, Andersson TB, Ingelman-Sundberg M, Heins N. Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. *J Biotechnol.* 2010; 145:284-94. Epub 2009 Nov 20.
379. Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. *Hum Genet.* 2010; 127:1-17
380. Gomez A, Nekvindova J, Travica S, Lee MY, Johansson I, Edler D, Mkrtchian S, Ingelman-Sundberg M. Colorectal cancer specific cytochrome P450 2W1 (CYP2W1): intracellular localization, glycosylation, and catalytic activity. *Mol Pharmacol.* 2010 ;78:1004-11.
381. Mwinyi, J, Cavaco, I, Steen Pedersen, R. Persson, A., Burkhardt, S., Mkrtchian S. and Ingelman-Sundberg M. Regulation of CYP2C19 expression by estrogen receptor alpha. Implications for estrogen dependent inhibition of drug metabolism. *Mol Pharmacol* 2010;;78:886-94
382. Wang J, Hu Y, Nekvindova J, Ingelman-Sundberg M, Neve EP. IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. *Biochem Pharmacol.* 2010; 80:1592-600. Epub 2010 Aug 17.
383. Ingelman-Sundberg M, Sim SC. Intronic polymorphisms of cytochromes P450. *Hum Genomics.* 2010; 4:402-5.
384. Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. *Hum Mutat.* 2011 ;32:526-31.
385. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. *Trends Pharmacol Sci.* 2011;32:72-81
386. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology--with emphasis on cytochrome P450. *Toxicol Sci.* 2011 ;120:1-13.
387. Yildirimman R, Brolén G, Vilardell M, Eriksson G, Synnergren J, Gmuender H, Kamburov A, Ingelman-Sundberg M, Castell J, Lahoz A, Kleinjans J, van Delft J, Björquist P, Herwig R. Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. *Toxicol Sci.* 2011 124:278-90
388. Mandenius CF, Andersson TB, Alves PM, Batzl-Hartmann C, Björquist P, Carrondo MJ, Chesne C, Coecke S, Edsbagge J, Fredriksson JM, Gerlach JC, Heinzle E, Ingelman-Sundberg M, Johansson I, Küppers-Munther B, Müller-Vieira U, Noor F,

- Zeilinger K. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project. *Altern Lab Anim.* 2011;39:147-71.
389. Kacevska M, Ivanov M, Ingelman-Sundberg M. Perspectives on epigenetics and its relevance to adverse drug reactions. *Clin Pharmacol Ther.* 2011;89:902-7.
 390. Mwinyi J, Cavaco I, Yurdakok B, Mkrtchian S, Ingelman-Sundberg M. The ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression. *J Pharmacol Exp Ther.* 2011;338:302-9.
 391. Sivertsson L, Edebert I, Porsmyr Palmertz M, Ingelman-Sundberg M, Neve EP. Induced CYP3A4 Expression in Confluent Huh7 Hepatoma Cells as a Result of Decreased Cell Proliferation and Subsequent PXR Activation. *Mol Pharmacol.* 2013 Mar;83(3):659-70. doi: 10.1124/mol.112.082305. Epub 2012 Dec 21.
 392. Eliasson E, Sim SC, Rane A, Ingelman-Sundberg M. Institutional profile: Karolinska institutet. *Pharmacogenomics.* 2012 Dec;13(16):1887-91
 393. Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. *Clin Pharmacol Ther.* 2012;92:727-36
 394. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. *Pharmacogenomics J.* 2012 Oct 23.
 395. Peyrot WJ, Middeldorp CM, Jansen R, Smit JH, de Geus EJ, Hottenga JJ, Willemsen G, Vink JM, Virding S, Barragan I, Ingelman-Sundberg M, Sim SC, Boomsma DI, Penninx BW. Strong effects of environmental factors on prevalence and course of major depressive disorder are not moderated by 5-HTTLPR polymorphisms in a large Dutch sample. *J Affect Disord.* 2012 Sep 26.
 396. Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P, Edler D. The expression of CYP2W1: a prognostic marker in colon cancer. *Anticancer Res.* 2012;32:3869-74.
 397. Sivertsson L, Synnergren J, Jensen J, Björquist P, Ingelman-Sundberg M. Hepatic Differentiation and Maturation of Human Embryonic Stem Cells Cultured in a Perfused Three-Dimensional Bioreactor. *Stem Cells Dev* 2013;22:581-94.
 398. Kacevska M, Ivanov M, Ingelman-Sundberg M. Epigenetic-dependent regulation of drug transport and metabolism: an update. *Pharmacogenomics.* 2012 ;13:1373-85.
 399. Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, Rane A, Ingelman-Sundberg M. DNA methylation dynamics in the hepatic CYP3A4 gene promoter. *Biochimie.* 2012;94:2338-44.
 400. Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Eliasson E. UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. *Clin Pharmacol Ther.* 2012;92:221-7.
 401. Neve EP, Nordling A, Andersson TB, Hellman U, Diczfalusy U, Johansson I, Ingelman-Sundberg M. Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria. *J Biol Chem.* 2012;287:6307-17.
 402. Lawson EB, Wu JC, Baldwin RM, Ingelman-Sundberg M, Rosenborg S, Yim DS, Yin OQ, Capparelli EV, Ma JD. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. *Eur J Clin Pharmacol.* 2012;68:407-13.
 403. Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. *Eur J Clin Pharmacol.* 2012;68:397-406.

404. Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S, Uher R, Gunasinghe C, Gray J, Campbell D, Hauser J, Maier W, Marusic A, Rietschel M, Perez J, Giovannini C, Mors O, Mendlewicz J, McGuffin P, Farmer AE, Ingelman-Sundberg M, Craig IW, Aitchison KJ. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. *J Psychopharmacol*. 2012;26:398-407.
405. Ivanov M, Kals M, Kacevska M, Metspalu A, Ingelman-Sundberg M, Milani L. In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. *Nucleic Acids Res*. 2013, 41(6):e72. doi: 10.1093/nar/gks1467. Epub 2013 Jan 15
406. Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN. Characterisation of Human Cytochrome P450s Involved in the Bioactivation of Clozapine. *Drug Metab Dispos*. 2013 Mar;41(3):651-8. doi: 10.1124/dmd.112.050484. Epub 2013 Jan 7 2013 . [Epub ahead of print]
407. Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. *Clin Cancer Res*. 2013 Apr 15. [Epub ahead of print]
408. Choong E, Loryan I, Lindqvist M, Nordling A, Elbouazzaoui S, van Schaik RH, Johansson I, Jakobsson J, Ingelman-Sundberg M. Sex Difference in Formation of Propofol Metabolites: A Replication Study. *Basic Clin Pharmacol Toxicol*. 2013 Mar 25. doi: 10.1111/bcpt.12070. [Epub ahead of print]
409. Sim SC, Ingelman-Sundberg M. Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. *Methods Mol Biol*. 2013;987:251-9. doi: 10.1007/978-1-62703-321-3_21.
410. Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, Noor F. 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies. *Toxicol Sci*. 2013 May;133(1):67-78. doi: 10.1093/toxsci/kft021. Epub 2013 Feb 1.
411. Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, Ingelman-Sundberg M. High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. *Pharmacogenomics J*. 2013 Dec 10. doi: 10.1038/tpj.2013.41. [Epub ahead of print]
412. Stenstedt K, Travica S, Guo J, Barragan I, Pors K, Patterson L, Edler D, Mkrtchian S, Johansson I, Ingelman-Sundberg M. CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer. *Pharmacogenomics*. 2013 Oct;14(13):1615-22. doi: 10.2217/pgs.13.136.
413. Ivanov M, Kals M, Kacevska M, Barragan I, Kasuga K, Rane A, Metspalu A, Milani L, Ingelman-Sundberg M. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. *Genome Biol*. 2013 Aug 19;14(8):R83. [Epub ahead of print]
414. Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, Osawa Y. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. *Drug Metab Dispos*. 2013 Oct;41(10):1725-31.
415. Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. *Mol Psychiatry*. 2013 Jul 23. doi: 10.1038/mp.2013.89. [Epub ahead of print]
416. Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K. Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and

- CYP2W1 for biological activity. *J Med Chem.* 2013 Aug 8;56(15):6273-7. doi: 10.1021/jm4000209. Epub 2013 Jul 26.
417. Neve EP, Artursson P, Ingelman-Sundberg M, Karlgren M. An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux. *Mol Pharm.* 2013 Aug 5;10(8):3152-63. doi: 10.1021/mp400202d. Epub 2013 Jul 15.
 418. Stenstedt K, Hallstrom M, Lédel F, Ragnhammar P, Ingelman-Sundberg M, Johansson I, Edler D. The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases. *Acta Oncol.* 2014 Mar 13. [Epub ahead of print]
 419. Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique Distribution of CYP2A6 Variant Alleles in Ethiopian Population. *OMICS.* 2013 Dec 31. [Epub ahead of print]
 420. Stenstedt K, Hallstrom M, Lédel F, Ragnhammar P, Ingelman-Sundberg M, Johansson I, Edler D. The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases. *Acta Oncol.* 2014;53:885-91
 421. Persson A and Ingelman-Sundberg M: Pharmacogenomics of cytochrome P450 dependent metabolism of endogenous compounds: Implications for behavior, psychopathology and treatment. *J Pharmacogenomics Pharmacoproteomics* 2014, 5:2
 422. Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. *Trends Pharmacol Sci.* 2014;35:384-396.
 423. Holmgren G, Sjögren AK, Barragan I, Sabirsh A, Sartipy P, Synnergren J, Björquist P, Ingelman-Sundberg M, Andersson TB, Edsbacke J. Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. *Drug Metab Dispos.* 2014; 42:1401-6.
 424. Ingelman-Sundberg M, Persson A, Jukic MM. Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. *Pharmacogenomics.* 2014;15:1841-4.
 425. Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, Alghanem AF, Cross MJ, Ellis EC, Ingelman-Sundberg M, Malik HZ, Kitteringham NR, Goldring CE, Park BK. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. *Free Radic Biol Med.* 2015; 78:202-12.
 426. Apellániz-Ruiz M, Inglada-Pérez L, Naranjo ME, Sánchez L, Mancikova V, Currás-Freixes M, de Cubas AA, Comino-Méndez I, Triki S, Rebai A, Rasool M, Moya G, Grazina M, Opocher G, Cascón A, Taboada-Echalar P, Ingelman-Sundberg M, Carracedo A, Robledo M, Llerena A, Rodríguez-Antona C. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. *Pharmacogenomics J.* 2014. doi: 10.1038/tpj.2014.67. [Epub ahead of print]
 427. Bonder MJ, Kasela S, Kals M, Tamm R, Lokk K, Barragan I, Buurman WA, Deelen P, Greve JW, Ivanov M, Rensen SS, van Vliet-Ostaptchouk JV, Wolfs MG, Fu J, Hofker MH, Wijmenga C, Zhernakova A, Ingelman-Sundberg M, Franke L, Milani L. Genetic

- and epigenetic regulation of gene expression in fetal and adult human livers. *BMC Genomics*. 2014;15:860. 15:860. doi: 10.1186/1471-2164-15-860.
428. Holmgren G, Sjögren AK, Barragan I, Sabirsh A, Sartipy P, Synnergren J, Björquist P, Ingelman-Sundberg M, Andersson TB, Edsbacke J. Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. *Drug Metab Dispos*. 2014; 42:1401-6.10.
429. Ingelman-Sundberg M, Persson A, Jukic MM. Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. *Pharmacogenomics*. 2014;15:1841-4.
430. Persson A, Sim SC, Viriding S, Onishchenko N, Schulte G, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. *Mol Psychiatry*. 2014;19:733-41.
431. Ingelman-Sundberg M. Personalized medicine into the next generation. *J Intern Med*. 2015;277:152-4.
432. Apellániz-Ruiz M, Lee MY, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, García-Estévez L, Sereno M, García-Donás J, Castelo B, Guerra E, Leandro-García LJ, Cascón A, Johansson I, Robledo M, Ingelman-Sundberg M, Rodríguez-Antona C. Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy. *Clin Cancer Res*. 2015;21:322-8.
433. Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, Ingelman-Sundberg M, Papaluca-Amati M. Pharmacogenomic information in drug labels: European Medicines Agency perspective. *Pharmacogenomics J*. 2015 Jun;15(3):201-10.
434. Suter-Dick L, Alves PM, Blaauboer BJ, Bremm KD, Brito C, Coecke S, Flick B, Fowler P, Hescheler J, Ingelman-Sundberg M, Jennings P, Kelm JM, Manou I, Mistry P, Moretto A, Roth A, Stedman D, van de Water B, Beilmann M; Stem cell derived (SCD) systems in toxicology assessment. *Stem Cells Dev*. 2015 Feb 12. [Epub ahead of print]
435. Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, Alghanem AF, Cross MJ, Ellis EC, Ingelman-Sundberg M, Malik HZ, Kitteringham NR, Goldring CE, Park BK. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. *Free Radic Biol Med*. 2015 Jan;78:202-12.
436. Choong E., Guo J, Persson A, Viriding S., Johansson I., Mkrtchian S, Ingelman-Sundberg M. Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors. *PLoS One*. 2015 Apr 6;10(4):e0122820.
437. Lee MY, Apellániz-Ruiz M, Johansson I, Vikingsson S, Troels JK, Bergmann K, Brøsen K, Green H, Rodríguez-Antona C, Ingelman-Sundberg M. The role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. *Pharmacogenomics*. 2015 Jun;16(9):929-37.
438. Ingelman-Sundberg M. Interview with Magnus Ingelman-Sundberg. *Trends Pharmacol Sci*. 2015 Feb;36(2):65-7

439. Fujikura K, Ingelman-Sundberg M, Lauschke VM. Genetic variation in the human cytochrome P450 supergene family. *Pharmacogenet Genomics*. 2015 Dec;25(12):584-94.
440. Peric D, Barragan I, Giraud-Triboult K, Egesipe AL, Meyniel-Schicklin L, Cousin C, Lotteau V, Petit V, Touhami J, Battini JL, Sitbon M, Pinset C, Ingelman-Sundberg M, Laustriat D, Peschanski M. Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells. *Stem Cells*. 2015 Oct;33(10):2936-48.
441. Sison-Young RL, Mitsa D, Jenkins RE, Mottram D, Alexandre E, Richert L, Aerts H, Weaver RJ, Jones RP, Johann E, Hewitt PG, Ingelman-Sundberg M, Goldring CE, Kitteringham NR, Park BK. Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. *Toxicol Sci*. 2015 Oct;147(2):412-24.
442. Lauschke VM, Hendriks DF, Bell CC, Andersson TB, Ingelman-Sundberg M. Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. *Chem Res Toxicol*. 2016 Dec 19;29(12):1936-1955.
443. Dragovic S, Vermeulen NP, Gerets HH, Hewitt PG, Ingelman-Sundberg M, Park BK, Juhila S, Snoeys J, Weaver RJ. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. *Arch Toxicol*. 2016 Dec;90(12):2979-3003.
444. Ivanov M, Kals M, Lauschke V, Barragan I, Ewels P, Käller M, Axelsson T, Lehtiö J, Milani L, Ingelman-Sundberg M. Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression. *Nucleic Acids Res*. 2016 Aug 19;44(14):6756-69. doi: 10.1093/nar/gkw316
445. Guo J, Johansson I, Mkrtchian S, Ingelman-Sundberg M. The CYP2W1 enzyme: regulation, properties and activation of prodrugs. *Drug Metab Rev*. 2016 Aug;48(3):369-78. doi: 10.1080/03602532.2016.1188939
446. Lauschke VM, Ingelman-Sundberg M. Requirements for comprehensive pharmacogenetic genotyping platforms. *Pharmacogenomics*. 2016 Jun;17(8):917-24. doi: 10.2217/pgs-2016-0023.
447. Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, Fredriksson Puigvert L, Dankers AC, Jacobs F, Snoeys J, Sison-Young RL, Jenkins RE, Nordling Å, Mkrtchian S, Park BK, Kitteringham NR, Goldring CE, Lauschke VM, Ingelman-Sundberg M. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. *Sci Rep*. 2016 May 4;6:25187. doi: 10.1038/srep25187.
448. Ingelman-Sundberg M, Cascorbi I. Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal? *Clin Pharmacol Ther*. 2016 May;99(5):478-80. doi: 10.1002/cpt.351.

449. Nebert DW, Ingelman-Sundberg M. What do animal experiments tell us that in vitro systems cannot? The Human Toxome Project. *Regul Toxicol Pharmacol*. 2016 Mar;75:1-4. doi: 10.1016/j.yrtph.2015.09.027.
450. Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. *Clin Pharmacol Ther*. 2016 Feb;99(2):172-85. doi: 10.1002/cpt.280.
451. Guo J, Thiess S, Johansson I, Mkrtchian S, Ingelman-Sundberg M. Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1. *FEBS Lett*. 2016 Feb;590(3):330-9. doi: 10.1002/1873-3468.12063.
452. Lauschke VM, Ingelman-Sundberg M. Precision Medicine and Rare Genetic Variants. *Trends Pharmacol Sci*. 2016 Feb;37(2):85-86. doi: 10.1016/j.tips.2015.10.006.
453. Stacey GN, Coecke S, Price AB, Healy L, Jennings P, Wilmes A, Pinset C, Ingelman-Sundberg M, Louisse J, Haupt S, Kidd D, Robitski A, Jahnke HG, Lemaitre G, Myatt G. Ensuring the Quality of Stem Cell-Derived In Vitro Models for Toxicity Testing. *Adv Exp Med Biol*. 2016;856:259-297.
454. Pradip A, Steel D, Jacobsson S, Holmgren G, Ingelman-Sundberg M, Sartipy P, Björquist P, Johansson I, Edsbacke J. High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis. *Stem Cells Int*. 2016;2016:2475631. doi: 10.1155/2016/2475631.
455. Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments. *AAPS J*. 2017 Nov 27;20(1):4. doi: 10.1208/s12248-017-0161-x.
456. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. *Clin Pharmacol Ther*. 2017 Oct;102(4):688-700. doi: 10.1002/cpt.690.
457. Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy. Lauschke VM, Ivanov M, Ingelman-Sundberg M. *Trends Pharmacol Sci*. 2017 Sep;38(9):765-770.
458. Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, Renblom A, Sim SC, Peñas-Lledó EM, Courtet P, Llerena A, Baune BT, de Quervain DJ, Papassotiropoulos A, Tyndale RF, Binder EB, Dannlowski U, Ingelman-Sundberg M. Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. *Mol Psychiatry*. 2017 Aug;22(8):1224. doi: 10.1038/mp.2017.93
459. Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, Renblom A, Sim SC, Peñas-Lledó EM, Courtet P, Llerena A, Baune BT, de Quervain DJ,

- Papassotiropoulos A, Tyndale RF, Binder EB, Dannlowski U, Ingelman-Sundberg M. Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. *Mol Psychiatry*. 2017 Aug;22(8):1155-1163. doi: 10.1038/mp.2016.204
460. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. *Clin Pharmacol Ther*. 2017 Jul;102(1):152. doi: 10.1002/cpt.725.
461. Vorrink SU, Ullah S, Schmidt S, Nandania J, Velagapudi V, Beck O, Ingelman-Sundberg M, Lauschke VM. Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. *FASEB J*. 2017 Jun;31(6):2696-2708. doi: 10.1096/fj.201601375R.
462. Bell CC, Lauschke VM, Vorrink SU, Palmgren H, Duffin R, Andersson TB, Ingelman-Sundberg M. Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury. *Drug Metab Dispos*. 2017 Apr;45(4):419-429. doi: 10.1124/dmd.116.074369.
463. Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, Jeong H, Morgan ET, Turnbaugh PJ, Klaassen CD, Bhatt AP, Redinbo MR, Hao P, Waxman DJ, Wang L, Zhong XB. Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). *Acta Pharm Sin B*. 2017 Mar;7(2):241-248. doi: 10.1016/j.apsb.2016.12.006.
464. Sison-Young RL, Lauschke VM, Johann E, Alexandre E, Antherieu S, Aerts H, Gerets HHJ, Labbe G, Hoët D, Dorau M, Schofield CA, Lovatt CA, Holder JC, Stahl SH, Richert L, Kitteringham NR, Jones RP, Elmasry M, Weaver RJ, Hewitt PG, Ingelman-Sundberg M, Goldring CE, Park BK. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. *Arch Toxicol*. 2017 Mar;91(3):1385-1400. doi: 10.1007/s00204-016-1745-4.
465. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. *Clin Pharmacol Ther*. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602.
466. Goldring C, Antoine DJ, Bonner F, Crozier J, Denning C, Fontana RJ, Hanley NA, Hay DC, Ingelman-Sundberg M, Juhila S, Kitteringham N, Silva-Lima B, Norris A, Pridgeon C, Ross JA, Young RS, Tagle D, Tornesi B, van de Water B, Weaver RJ, Zhang F, Park BK. Stem cell-derived models to improve mechanistic understanding

- and prediction of human drug-induced liver injury. *Hepatology*. 2017 Feb;65(2):710-721. doi: 10.1002/hep.28886.
467. Lauschke VM, Mkrtchian S, Ingelman-Sundberg M. The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration. *Biochem Biophys Res Commun*. 2017 Jan 15;482(3):399-407. doi: 10.1016/j.bbrc.2016.10.084.
 468. Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. *Genet Med*. 2017 Jan;19(1):20-29. doi: 10.1038/gim.2016.33
 469. Copple IM, den Hollander W, Callegaro G, Mutter FE, Maggs JL, Schofield AL, Rainbow L, Fang Y, Sutherland JJ, Ellis EC, Ingelman-Sundberg M, Fenwick SW, Goldring CE, van de Water B, Stevens JL, Park BK. Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. *Arch Toxicol*. 2018 Nov 13. doi: 10.1007/s00204-018-2354-1.
 470. Haslemo T, Eliasson E, Jukić MM, Ingelman-Sundberg M, Molden E. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. *Br J Clin Pharmacol*. 2018 Oct 12. doi: 10.1111/bcp.13788.
 471. Parmentier C, Hendriks DFG, Heyd B, Bachellier P, Ingelman-Sundberg M, Richert L. Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent. *Toxicol Lett*. 2018 Oct 1;295:187-194. doi: 10.1016/j.toxlet.2018.06.1069.
 472. Kozyra M, Johansson I, Nordling Å, Ullah S, Lauschke VM, Ingelman-Sundberg M. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. *Sci Rep*. 2018 Sep 24;8(1):14297.
 473. Ingelman-Sundberg M, Lauschke VM. Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions. *Pharmacogenomics*. 2018 Sep 1;19(14):1133-1138. doi: 10.2217/pgs-2018-0096.
 474. Baze A, Parmentier C, Hendriks DFG, Hurrell T, Heyd B, Bachellier P, Schuster C, Ingelman-Sundberg M, Richert L. Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. *Tissue Eng Part C Methods*. 2018 Sep;24(9):534-545. doi: 10.1089/ten.TEC.2018.0134.
 475. Ingelman-Sundberg M, Lauschke VM. Current Statistical Metrics Are Pragmatic Measures to Compare the Predictive Quality of Preclinical Assays. *Toxicol Sci*. 2018 Sep 1;165(1):4-5. doi: 10.1093/toxsci/kfy160.
 476. Jukic MM, Lauschke VM, Saito T, Hiratsuka M, Ingelman-Sundberg M. Functional characterization of CYP2D7 gene variants. *Pharmacogenomics*. 2018 Aug 1;19(12):931-936.
 477. Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, Rodríguez-Antona C. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. *Genet Med*. 2018 Jun;20(6):622-629. doi: 10.1038/gim.2017.156.

478. Vorriink SU, Zhou Y, Ingelman-Sundberg M, Lauschke VM. Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions. *Toxicol Sci*. 2018 Jun 1;163(2):655-665. doi: 10.1093/toxsci/kfy058.
479. Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM. Integrating rare genetic variants into pharmacogenetic drug response predictions. *Hum Genomics*. 2018 May 25;12(1):26. doi: 10.1186/s40246-018-0157-3.
480. Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. *Am J Psychiatry*. 2018 May 1;175(5):463-470. doi: 10.1176/appi.ajp.2017.17050550.
481. Lauschke VM, Ingelman-Sundberg M. How to Consider Rare Genetic Variants in Personalized Drug Therapy. *Clin Pharmacol Ther*. 2018 May;103(5):745-748. doi: 10.1002/cpt.976.
482. Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C, Goldring CE, Park K, Regan SL, Walker T, Schofield C, Baze A, Foster AJ, Williams DP, van de Ven AWM, Jacobs F, Houdt JV, Lähteenmäki T, Snoeys J, Juhila S, Richert L, Ingelman-Sundberg M. Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study. *Toxicol Sci*. 2018 Apr 1;162(2):655-666. doi: 10.1093/toxsci/kfx289.
483. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE; PharmVar Steering Committee. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. *Clin Pharmacol Ther*. 2018 Mar;103(3):399-401. doi: 10.1002/cpt.910.
484. Lauschke VM, Barragan I, Ingelman-Sundberg M. Pharmacoepigenetics and Toxicopigenetics: Novel Mechanistic Insights and Therapeutic Opportunities. *Annu Rev Pharmacol Toxicol*. 2018 Jan 6;58:161-185. doi: 10.1146/annurev-pharmtox-010617-053021.
485. Ewart L, Dehne EM, Fabre K, Gibbs S, Hickman J, Hornberg E, Ingelman-Sundberg M, Jang KJ, Jones DR, Lauschke VM, Marx U, Mettetal JT, Pointon A, Williams D, Zimmermann WH, Newham P. Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. *Annu Rev Pharmacol Toxicol*. 2018 Jan 6;58:65-82. doi: 10.1146/annurev-pharmtox-010617-052722.